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Liver cancer is a disease that is more prevalent in Asia than the rest of the 
world. Of the various types of liver cancers, hepatocellular carcinoma (HCC) is the 
most common. The development of HCC is a multi-step process. During this process, 
the aberrant expression and activities of various genes contribute to the survival and 
proliferation of tumor cells. One family of proteins that is known to suppress the 
expression of tumor suppressor genes is histone deacetylase (HDAC). The inhibition 
of HDACs, by means of various classes of drugs collectively known as HDAC 
inhibitors, is currently being examined as a strategy to kill tumor cells. 
In this study, we identified two members of the HDAC family to be highly 
expressed in human HCC tissue. Both HDAC1 and HDAC2 were upregulated in the 
HCC tumors compared to the matched non-tumor controls, and HDAC1 expression 
was found to be correlated with poor prognosis in the patients. When both HDAC1 
and 2 were silenced in HCC cell lines, there was reduced colony formation, reduced 
proliferation, and increased apoptosis in the cells. These effects are attributed to the 
enzymatic activities of these 2 proteins, which have a compensatory effect on each 
other’s expressions and activities. In addition, we also examined the change in gene 
expression profiles in HCC cells when HDAC1 and 2 were silenced individually and 
together, in comparison to the use of HDAC inhibitor PXD101. 
Together, these results established the critical roles of HDAC1 and 2 in the 
survival and proliferation of HCC cells. We have also elicited their mechanism of 
actions by demonstrating the importance of their enzymatic activity as well as the 
compensatory effects on each other. Understanding these 2 members of the HDAC 
family would have significant impact on the design and use of HDAC inhibitors in the 













 CHAPTER 1 INTRODUCTION 
 
1.1 Liver cancer  
1.1.1 High occurrence and high mortality 
Due to population aging and growth, cancer is fast becoming the leading cause 
of death. Liver cancer is the 5th most common cancer worldwide, with an alarming 
748,300 new cases and 695,900 cancer deaths in 2008 (Jemal et al., 2011). The 
highest liver cancer rate is in East and Southeast Asia, with over half of the cases 
worldwide occurring in China alone. Between 1988 to 2001, the 5-year survival rate 
of liver cancer patient is only 8% in the United States and 5% in developing countries 
(Chuang et al., 2009).  
1.1.2 Hepatocellular carcinoma (HCC) 
There are many forms of liver cancers with different histological types. These 
include hepatocellular carcinoma, childhood hepatoblastoma, adult 
cholangiocarcinoma which originates from the intrahepatic biliary ducts, and 
angiosarcoma which originates from the intrahepatic blood vessels (Chuang et al., 
2009). Of these, hepatocellular carcinoma (HCC) is the most common, accounting for 
85% to 90% of all primary liver cancers (El-Serag and Rudolph, 2007). It frequently 
occurs in a liver with chronic hepatitis and cirrhosis, where many hepatocytes die and 
there is invasion by inflammatory cells and fibrosis (Thorgeirsson and Grisham, 2002). 
 
1.2 Risk Factors for HCC 
1.2.1 Hepatitis B and Hepatitis C viruses 
The dominant risk factor for HCC is infection by Hepatitis B virus (HBV) or 
Hepatitis C virus (HCV). HBV infection is common in Asian countries excluding 
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Japan, which has more HCV-related cases. The virus can be transmitted from mother 
to child or via sexual intercourse. There is a 5- to 15-fold increased risk of HCC for 
HBV carriers compared to non-carriers (El-Serag and Rudolph, 2007). 
The HBV is a double-stranded DNA containing virus that belongs to the 
family Hepadnaviridae (Sanyal et al., 2010). It can cause necroinflammation of liver 
cells, leading to cirrhosis. Hepatocytes will proliferate in order to regenerate the 
damaged liver. This high turnover in hepatocytes could result in accumulation of 
genetic mutations of the cells. Consequently, there will be increase in genetic changes, 
chromosome rearrangement, as well as activation and inactivation of oncogenes and 
tumor suppressor genes respectively (But et al., 2008). In the absence of cirrhosis, the 
HBV can also integrate itself into the host’s genome, contributing to genomic 
instability (Szabo et al., 2004). Also, HBV produces HBx protein that is able to 
regulate expression of genes involved in cell proliferation, deregulate cell cycle 
control, and interfere with DNA repair and apoptosis (Feitelson, 1999).  
The HCV is a RNA-containing virus that belongs to the Hepacivirus genus of 
the Flaviviridae family (Szabo et al., 2004). It is unable to integrate into the host 
genome, but its core protein can enter the host cell and localize on the mitochondrial 
membrane and endoplasmic reticulum. This promotes oxidative stress for the infected 
cell. Signaling pathways will be activated to upregulate genes involved in cytokine 
production and eventually inflammation, changes in apoptotic pathway and tumor 
formation (Sheikh et al., 2008).  
1.2.2 Other risk factors 
Other than HBV and HCV infection, aflatoxin contamination of food is also a 
major risk factor for HCC. It occurs commonly in Southeast Asia and China, where 
there is improper storage of food such as cereals and peanuts. Aflatoxin is a 
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mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus and is 
carcinogenic (Chuang et al., 2009). Aflatoxin B1 can cause p53 mutation by G:C to 
T:A transversions at the 3rd base in codon 249 of the gene (Greenblatt et al., 1994). 
In addition, there is also evidence to suggest that alcohol drinking, smoking, obesity 
and diabetes as possible risk factors for HCC (Chuang et al., 2009). 
 
1.3 Current treatment of HCC and problems 
1.3.1 Diagnosis and staging 
Diagnosis of HCC is generally made by radiological imaging and measuring 
serum Alpha Fetoprotein (AFP) level. If a liver mass is detected in a patient with 
chronic hepatitis or cirrhosis, there is a high likelihood of HCC. Biopsy may or may 
not be needed to proceed with assessment for treatment.  
Tumor staging for HCC is done by tumor/node/metastasis (TNM) staging or 
Okuda staging system (Lau and Lai, 2008). The TNM system classifies tumors based 
on the size of the primary tumor (T), presence of lymph node metastasis (N), and 
distant metastasis (M), but does not look at liver function. On the other hand, Okuda 
staging system takes into account liver function such as presence of ascites, as well as 
albumin and bilirubin levels in the blood (Okuda et al., 1985). 
1.3.2 Liver resection 
The primary therapy for HCC is surgical resection of the liver. However, only 
10% to 30% of HCC patients are suitable for surgery at the time of diagnosis (Lau and 
Lai, 2008). There are many criteria to satisfy before recommending surgery. 
Unsuitable patients include those with tumors that are too large resulting in 
insufficient hepatic remnant after surgery which may lead to subsequent liver failure, 
multifocal tumors that are too extensive, and distant metastasis (Lau, 1997).  
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The major problem with liver resection as treatment for HCC is tumor 
recurrence (Portolani et al., 2006). Recurrence could be due to either intrahepatic 
dissemination of the primary tumor or de novo tumor development. Intrahepatic 
dissemination is usually the cause, evident from the fact that the presence of satellite 
nodules and microvascular invasion are the 2 main predictors for tumor recurrence 
(Adachi et al., 1995; Nagasue et al., 1993). Such recurrence commonly takes place 
within 3 years after surgery, and is characterized by multifocal and aggressive tumor 
(Imamura et al., 2003). Repeated hepatectomy can be done to treat recurrent disease 
with a 5-year survival of up to 50%, but re-recurrence rate is generally high (Itamoto 
et al., 2007). 
1.3.3 Liver transplantation 
Orthotopic liver transplantation is the best therapy for HCC, provided there is 
no macroscopic vascular invasion and metastasis. Not only does it remove the tumor 
burden, it also treats the underlying liver disease that could lead to recurrence in the 
patient. However, there are very limited number of organs available for transplant, 
leading to prolonged waiting time which is associated with high dropout rates as the 
disease progresses beyond selection criteria for transplant (Rahbari et al., 2011). 
Living donor liver transplantation can increase the pool of available donors. 
Nevertheless, there are many ethical issues to be considered given the donor 
morbidity of up to 40% and mortality of 0.5% (Trotter et al., 2002). In addition, there 
is a need for immunosuppression in patients receiving liver transplant. Two of such 
immunosuppressive drugs, Cyclosporine and Tacrolimus, have raised controversy for 
their use in HCC patients as they have been shown to have potential tumor-promoting 
effects (Guba et al., 2004). 
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1.3.4 Radiation therapy 
External beam radiation therapy is seldom used in HCC due to the low 
tolerance of the non-tumorous portion of the liver. It takes 120 Gy to kill the tumor 
cells in HCC while liver irradiation beyond 40 Gy can cause radiation-induced liver 
disease (Lawrence et al., 1995). Therefore, selective intra-arterial radiotherapy (SIRT) 
is used to deliver radioactive microspheres to the tumor internally. However, SIRT 
can also cause complications such as postembolic syndrome, characterized by fatigue, 
abdominal pain, and fever (Rahbari et al., 2011). 
1.3.5 Chemotherapy 
Systemic chemotherapy is used to treat patients with unresectable HCC. 
Doxorubicin is widely used in these patients but the response rate is very low (less 
than 20%) with no survival advantage (Lai et al., 1988). Other drugs such as 
Tamoxifen and Somatostatin have also been tested in clinical trials but results are not 
satisfactory. However, there has been some success in the clinical trial of the drug 
Sorafenib in recent years. Sorafenib is an oral multikinase inhibitor that can block cell 
proliferation and neoangiogionesis  (Wilhelm et al., 2008). In a multicenter phase III 
clinical trial on Sorafenib to treat 602 advanced HCC patients, the treatment group 
demonstrated 31% reduction in the risk of death and a longer median survival of 10.6 
months compared to 7.9 months in the placebo group (Llovet et al., 2008). The time 
to progression (TTP) based on independent radiological review was 5.5 months for 
patients treated with Sorafenib and 2.8 months for the control group. However, like 
most chemotherapy drugs, there were adverse side effects associated with the use of 
Sorafenib. These include diarrhea, fatigue, weight loss, and hand-foot skin reaction. 
Although there was no death related with toxicity being described, there was drug 




1.4 Molecular mechanisms of HCC development 
Just like many other types of cancer, the development of HCC is a multi-step 
process. Vogelstein proposed that there must be at least 3 genomic hits for solid tumor 
such as HCC to develop (Vogelstein and Kinzler, 2004). The risk factors mentioned 
in previous sections can set the stage for hepatocarcinogenesis by causing the initial 
damage to the liver. Additional genomic hits, in the form of mutations or epigenetic 
regulation, can alter key genes in the cancer pathways, thus inducing the cell to 
acquire malignant phenotype.  
According to Hanahan and Weinberg, pathways disrupted in cancer can be 
divided into 6 groups based on their functions: evading apoptosis, unlimited 
replicative potential,  self-sufficiency in growth signals, insensitivity to anti-growth 
signals, angiogenesis, and tumor invasion and metastasis (Hanahan and Weinberg, 
2000). Numerous pathways are affected due to molecular changes in 
hepatocarcinogenesis.  
1.4.1 Pathway involved in cell survival 
The 2 major pathways that are responsible for HCC cell survival are the Wnt 
and Hedgehog (Hh) signaling pathways. 
Upon binding of the Wnt ligand to the membrane receptor Frizzled, a cascade 
of events occurs. The axin/GSK-3/APC complex which normally promotes the 
degradation of beta catenin in the cytoplasm will be inhibited, allowing beta-catenin 
to now enter the nucleus to interact with the TCF/LEF family transcription factors. 
This leads to the transcription of various oncogenes, such as c-myc, cyclin D, and 
survivin, which are involved in cell survival. 
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Two important genes in the hedgehog signaling pathway, Sonic Hedgehog 
(SHH) and smoothened (SMO), are found to be overexpressed in many cases of HCC. 
This leads to the activation of the pathway (Lachenmayer et al., 2010). On the other 
hand, a negative regulator of the pathway Hedgehog-interacting protein (HHIP) is 
downregulated in many HCC cases by methylation and/or loss of heterozygosity. 
1.4.2 Pathways involved in cell proliferation 
The pathways contributing to HCC cell proliferation are mesenchymal-
epithelial transition factor (c-Met), insulin-like growth factor (IGF), Ras-mitogene 
activated protein kinase (Ras-MAPK), and PI3/Akt/mTOR, pathways. 
Hepatocyte growth factor (HGF) can activate the c-Met pathway which is 
responsible for invasive growth in cancer, angiogenesis, proliferation and migration 
(Villanueva et al., 2007). In HCC, upregulation of HGF in cirrhotic liver and c-Met 
amplification and mutation has been reported.  
In addition, the IGF pathway is also frequently activated in HCC (Villanueva 
et al., 2007). The upregulation of IGF-1 and IGF-2 and silencing of IGF binding 
proteins can lead to proliferation, as well as anti-apoptotic and invasive phenotype of 
the cell. IGF signaling can also activate the downstream Ras-MAPK pathway.  
The PI3/Akt/mTOR pathway is involved in numerous cellular processes such 
as proliferation, cell cycle progression, tumor growth, angiogenesis, apoptosis and cell 
differentiation. In HCC, poor prognosis has been associated with activated Akt, which 
can be activated by IGF signaling (Schmitz et al., 2008). Mammalian target of 
rapamycin (mTOR) can sense nutritional status and allow progression from G1 to S 




1.4.3 Apoptotic pathways 
Apoptosis, or programmed cell death, is a mechanism by which a cell dies 
after sustaining damage, with minimal disruption to its neighboring cells. One 
characteristic of many cancer cells is their ability to evade apoptosis. The activation of 
apoptosis is either by intrinsic stimulus such as DNA damage, or by extrinsic signals 
such as the binding of pro-apoptotic factors to the cell surface. The downregulation of 
pro-apoptotic factors (p53, Fas, PTEN, Bax, Bid) and the upregulation of many anti-
apoptotic factors (beta-catenin, Akt, RaS/ERKs, HGF, EGFR ligands, c-IAP1, NF-
kappaB, Snail) are observed in HCC (Fabregat et al., 2007). 
 
1.5 Epigenetic regulation in cancer 
There are many genes involved in the above mentioned pathways that are 
essential in hepatocarcinogenesis. The expression of these genes can be altered by 
genomic changes such as DNA mutation, deletion, amplifications and translocations. 
However, classical genetics alone cannot be used to explain how identical twins can 
have different phenotypes and susceptibilities to diseases (Esteller, 2008). 
Alternatively, gene expression can be regulated by epigenetic mechanisms. The term 
“epigenetics” was first used by Conrad Waddington about 70 years ago and its 
definition has evolved over time (Waddington, 1939). One of the most accepted 
definition described epigenetics as heritable changes in gene expression without 
changes in DNA sequences (Jones and Baylin, 2007). These include histone 
modification, DNA methylation, and microRNA expression.  
1.5.1 DNA methylation 
The human genome contains about 2-5% CpG dinucleotides (a cytosine next 
to a guanine) which mostly consists of repetitive sequences (Sincic and Herceg, 2011). 
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The CpG islands are located near the transcriptional start site in the promoter regions 
of many genes. DNA methylation is a process by which DNA methyltransferase 
(DNMT) transfers a methyl group to the carbon 5 position of the cytosine ring of the 
CpG dinucleotide covalently (Kanai, 2010). In normal cells, DNA methylation 
patterns are tissue-specific and gene specific. It is important in epigenetic 
reprogramming during development (Mann and Bartolomei, 2002). In cancer cells, 
there is dysregulation of DNA methylation, with hypermethylation at the gene 
promoter (CpG island specific) region as well as global hypomethylation  (Sincic and 
Herceg, 2011). The degree of methylation at the promoter region can impact gene 
expression by affecting the binding of transcription factors and methyl-binding 
proteins. The hypermethylation at the promoter results in the silencing of numerous 
tumor-suppressor genes as well as other cancer-associated genes, such as RB, VHL 
and E-cadherin (Kanai, 2010). The list of genes whose promoters are 
hypermethylated in cancer has been rapidly growing over the years. While 
hypermethylation at promoter region has been well-studied, much less is known about 
the global hypomethylation observed in cancer cell. It has been proposed that genes 
that are normally repressed in a healthy cells may be re-expressed in a cancer cell due 
to the loss of methylcytosine as observed in hypomethylation (Sincic and Herceg, 
2011). These includes proto-oncogenes and imprinted genes, as well as viral 
transposons that contribute to genomic instability (Esteller, 2008). In HCC, DNMT1 
mRNA expression is higher in liver tissue with chronic hepatitis or cirrhosis than that 
in normal livers, and even higher in HCC cases (Saito et al., 2001; Sun et al., 1997). 
The overexpression of DNMT1 in HCCs is also correlated with more poorly 
differentiated tumor types (Saito et al., 2003). In addition, Kondo et al. studied the 
methylation status of 8 CpG islands in non-cancerous and cancerous liver tissues and 
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found that it is higher in cancerous liver tissue (Kondo et al., 2000). In another study, 
the CpG methylation profile of HCC was done in a number of cancer-related 
promoters. By correlating the data with clinical outcomes in the patients, it was found 
that the methylation signature can be used to predict survival and clinical parameters 
such as grade and stage (Hernandez-Vargas et al., 2010). Taken together, DNA 
methylation is a mechanism by which molecular dsyregulation of genes occurs in 
HCC and has useful prognostic applications. 
1.5.2 MicroRNA 
MicroRNAs (miRNAs) are 22-nucleotide non-coding RNA that can bind to 
the 3’ untranslated region of their target mRNA in a sequence-specific manner, 
leading to mRNA degradation or translation inhibition (He and Hannon, 2004). The 
miRNA expression profiles was found to be different between normal and tumor, as 
well as among tumor types (Calin and Croce, 2006). In HCC cell line, the let-7 family 
of miRNA was shown to inhibit expression of Bcl-xL and enhanced sorafenib-
induced apoptosis (Shimizu et al., 2010). There are at least 25 aberrantly expressed 
miRNA and their respective targets identified in HCC (Huang and He, 2011). 
1.5.3 Histone modification 
In eukaryotes, DNA is coiled around 4 histone units (H2A, H2B, H3, and H4) 
to form nucleosomes. Other than their role as packaging material for DNA, histones 
are also involved in gene regulation, DNA damage repair, replication, and 
recombination (Lennartsson and Ekwall, 2009). The “tails” of the histones protrude 
out from the surface of the chromatin polymer, and can undergo posttranslational 
modification such as acetylation, ubiquitylation, sumolytion, phosphorylation, and 
methylation. Based on the histone code hypothesis, the distinct modification of the 
histone tails can act sequentially or in combination to form the “histone code” which 
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is read by other proteins to cause downstream biological events (Strahl and Allis, 
2000). Each histone unit has many modification sites subjected to different types of 
modifications: H2A contains 13 sites, H2B contains 12 sites, H3 contains 21 sites, and 
H4 contains 14 sites (Zhang et al., 2003). The modification at one site can also 
influence that at another. Therefore, the number of possible combination and 
permutation of the histone code is enormous. The histone code can be stable, making 
it inheritable from one cell generation to the next. It can also be transient, making it 
dynamic and subjected to changes depending on environmental signal and the cell’s 
physiological state.  
1.5.3.1 Histone acetylation and deacetylation 
Of the various types of histone modifications, histone acetylation is the most 
common and well-studied. Acetylation can neutralize the positive charge of the N-
termini of the histone lysine residues, thus reducing their affinity for DNA so that the 
histone can be displaced from the nucleosome, which will then unfold and allow 
access by transcriptional factors (Lee et al., 1993). In other words, the chromatin is in 
a more “relaxed” or opened state when the histone tail lysine residues are acetylated. 
This is generally associated with gene activation. On the other hand, deacetylation 
increases the ionic interaction between the negatively charged DNA and the positively 
charged histones, leading to condensed chromatin structure and gene silencing. The 
acetylation level is due to the balance of activities by 2 types of enzymes: the histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). Various cancers have 




1.6 Histone acetyltransferases (HATs) 
There are 2 types of HATs: the A-type HATs which are nuclear and transcription 
related; and B-type HATs which are involved in acetylation of histones (Grunstein, 
1997). Instead of binding directly to DNA, HATs are recruited to the promoter by 
transcription factors (Roth et al., 2001). Acetylation of lysine on histone tails is not a 
random event. HATs can have preference for one site over another. Also, HATs can 
interact with other HATs and transcription co-repressors and co-activators to form a 
functional protein complex (Marks et al., 2001). Other than histones, HATs can also 
target non-histones proteins known as factor acetyltransferases (FATs), such as p53 
and E2F (Roth et al., 2001). The acetylation of these proteins will affect their DNA 
binding property and their functions as transcription factors.  
In various hematological and epithelial cancers, genes that encodes for HATs 
such as p300 and CBP, are found to be mutated, translocated, amplified, or 
overexpressed (Marks et al., 2001). For example, missense mutation of p300 has been 
found in gastric and colorectal cancers (Giles et al., 1998). In HCC, the loss of 
heterozygosity around the CBP locus has been reported (Sakai et al., 1992). 
 
1.7 Histone deacetylase (HDAC) 
1.7.1 HDAC family of proteins in mammals 
HDAC enzymes were first discovered in yeast. There are 18 mammalian 
HDACs identified so far. They are classified into classes based on their homology to 
that in yeast (Ropero and Esteller, 2007). Class I HDAC, which includes HDAC 1, 2, 
3, and 8, are homologous to Rpd3 in yeast. They are ubiquitously expressed in the 
nucleus of many human tissues and cell lines. Class II HDACs are homologous to 
Hda1 and are subdivided into class IIa (HDAC 4, 7, and 9) and IIb (HDAC 6 and 10). 
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Their expression is tissue-specific, and can translocate between the cytoplasm and 
nucleus. Their primary substrates are non-histone proteins so they are more 
appropriately called lysine deacetylases (Marks and Xu, 2009). Class III HDACs, also 
known as sirtuins (SIRT1-7) are homologous to the yeast Sir2 family. They are 
dependent on coenzyme NAD+ for them to be active. Class IV has only one member 
HDAC11, which shares conserved residues with class I and II HDACs. 
1.7.2 HDACs can function in a protein complex 
HDAC do not directly bind to DNA. Instead, they are recruited to specific 
chromosome regions by transcription and chromatin-related factors to form large 
multiunit protein complexes (Yang and Seto, 2003). For example, a core complex 
consisting of HDAC1, HDAC2, and the histone chaperones retinoblastoma-associated 
proteins (RbAp) 48 and 46 can interact with SAP30 and Sin3 to form the Sin3 
corepressor complex, which can interact with sequence-specific DNA binding 
proteins to repress specific genes (Laherty et al., 1997). The same core complex can 
also interact with Methyl CpG binding domain 3 (MBD3), Metastasis-associated 
protein 2 (MTA2), and the ATP-dependent chromatin-remodeling protein Mi2 to 
form the NuRD corepressor complex, which has a more global effect on transcription 
repression but can also bind to gene-specific transcription factors (Verdin, 2006). 
Therefore, HDACs can exert different effects through different binding partners. 
1.7.3 Regulation of transcription by HDACs 
1.7.3.1 Gene silencing 
As mentioned in the previous section, deacetylation of histone tails can limit 
DNA accessibility to the transcriptional activators as well as promote association of 
silencer, thus cause gene silencing. Other than exerting its effect at the chromatin 
level, HDACs can directly target the transcription machinery by deacetylating TAFI68 
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to inhibit Polymerase1-dependent transcription (Muth et al., 2001). Also, while 
acetylation of transcriptional activators can affect their DNA-binding ability, stability, 
activation potential, nuclear localization and coactivator interaction, deacetylation can 
reverse these effects (Yang and Seto, 2003). It has been demonstrated that the class III 
HDAC SIRT1 can deacetylate p53 to inhibit its DNA-binding and transcriptional 
activation activity, thereby blocking its function in cellular senescence and apoptosis 
(Langley et al., 2002; Luo et al., 2001). 
1.7.3.2 Gene activation 
Despite the conventional mechanism of HDAC repressing gene expression, 
there has been evidence that HDAC is involved in gene activation. A member of the 
class I HDAC in yeast, Hos2, has been shown to be required for efficient gene 
transcription (Wang et al., 2002). In addition, HDAC activity was needed for the 
Mouse mammary tumor virus (MMTV) promoter to function (Lee et al., 2011b). It 
was proposed that the recruitment of Polymerase II requires the deacetylation of the 
proteins that are part of the reinitiation scaffold, and inhibition of HDAC would 
impair this recruitment, leading to decreased rate of transcriptional initiation.  
1.7.4 Regulation of HDACs 
There are post-translational modifications that regulate HDACs functions. 
Inhibition of phosphatase can disrupt HDAC1 and HDAC2 complexes by increasing 
their phosphorylation (Galasinski et al., 2002; Pflum et al., 2001). On the other hand, 
these HDAC complexes are stabilized by specific phosphorylation by casein kinase 2 
(CK2) (Tsai and Seto, 2002). These apparent contradicting effects of phosphorylation 
on HDAC functions may imply that the effect is site-specific. In addition, 
sumoylation of HDAC1 is needed for its cell-cycle arrest and apoptotic response 
(David et al., 2002). Other than post-translational modification, it was recently 
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discovered that lipid sphingosine-1-phosphate (S1P) can bind to and inhibit the 
activity of both HDAC1 and HDAC2 (Hait et al., 2009). Also, recombinant HDACs 
produced in vitro are inactive, implying that co-factors such as Rb and MTA2 are 
necessary for their activation and function in vivo (Guenther et al., 2001).  
 
1.8 HDAC1 and 2 
1.8.1 Phylogenetic ancestry 
Both HDAC1 and HDAC2 belong to class I HDACs and are highly 
homologous. They share 83% amino acids identity (Yang and Seto, 2008). 
Phylogenetic analysis have shown that HDAC1 and HDAC2 genes originated from a 
single ancestor after a gene duplication event (Gregoretti et al., 2004). Gene 
duplication usually results in functional diversification when one of the 2 paralogs 
acquires new function or tissue-specific distribution. However, based on the strong 
sequence constraint between HDAC1 and 2, and that this gene duplication leading to 
HDAC1 and 2 was relatively recent, it was predicted that little functional divergence 
has taken place (Gregoretti et al., 2004). While this may be true in some biological 
processes, there is also evidence to suggest distinct functions of HDAC1 and 2 and 
they will be discussed in subsequent sections. 
1.8.2 Structure 
The HDAC1 and 2 proteins contain several domains. The largest and most 
important of these is the N-terminal catalytic domain which consists over 300 amino 
acids. The active site on the catalytic domain is a pocket with 2 adjacent histidine 
residues, 2 aspartic acid residues, and 1 tyrosine residue to form a “charge-relay” 
system with an essential Zn2+ ion (Brunmeir et al., 2009). When the Zn2+ ion is 
displaced from the pocket, such as by HDAC inhibitors, the charge-relay system 
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cannot function. There is also the N-terminal HDAC association domain (HAD) 
which is important for homo- and heterodimerization (Taplick et al., 2001), and the C-
terminal IACEE domain that is important to binding with pRb (Brehm et al., 1998).  
In addition to these domains that are common between HDAC1 and HDAC2, there 
are those that are found uniquely on HDAC1 or HDAC2. There is a nuclear 
localization signal (NLS) at the C-terminal of HDAC1 that is not found in HDAC2 
(Taplick et al., 2001). There is also a previously unrecognized region at the C-
terminal of HDAC2 predicted to have high propensity for coiled-coil (Gregoretti et al., 
2004). This may imply that HDAC2 can have protein-protein interaction with unique 
partners to execute differential functions from HDAC1.  
1.8.3 Functions in normal cells development 
HDAC1 is essential for embryonic development. Knocking out both HDAC1 
alleles in mice was embryonic lethal before E10.5, due to proliferation defects and 
retarded development (Lagger et al., 2002). Aberrant development was observed as 
early as E7.5. In these HDAC1-deficient mice, there was significant reduction in 
deacetylase activity in the Sin3 and NuRD complexes, as well as increase in levels of 
cyclin-dependent kinase inhibitors p21 and p27 in the embryonic stem cells. 
On the other hand, the effect of knocking out HDAC2 in mice is not as 
straightforward. Montgomery et al. found that HDAC2 knockout mice can survive 
until the perinatal period but die shortly after, due to multiple cardiac defects 
(Montgomery et al., 2007). These defects include loss of the right ventricle lumen of 
the heart, with thickened interventricular septum as well as increased apoptosis. 
However, when a conditional knockout was done to delete HDAC2 specifically in the 
heart, the mice were able to survive to adulthood without gross cardiac abnormality. 
Another group did not observe lethality in HDAC2 knockout mice despite its 
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involvement in cardiac function (Trivedi et al., 2007). Interestingly, one group found 
reduction in cell number as well as the thickness of the intestinal mucosa, and a body 
weight reduction of up to 40% in HDAC2-null mice (Zimmermann et al., 2007).  
In addition to its role in cardiac development, HDAC2 was also found to be involved 
in regulating memory formation and synaptic plasticity (Guan et al., 2009).  
 
1.9 Cooperative and distinct functions of HDAC1 and 2 
1.9.1 Redundancy of HDAC1 and HDAC2 functions 
With a high homology between HDAC1 and 2 and their co-existence in the 
same protein complexes, one would expect some redundancy in their functions. 
Several experiments suggest that HDAC1 and 2 may compensate for the function of 
the other. 
Firstly, despite the cardiac abnormality observed in HDAC2-null mice, 
Montgomery’s group did not find any abnormality after knocking out HDAC2 
specifically in the heart (Montgomery et al., 2007). It was only when a double 
deletion of both HDAC1 and HDAC2 was done in the heart that the knockout mice 
displayed postnatal lethality at day 14 with increased apoptosis in the heart. Secondly, 
it was demonstrated that while ablation of either HDAC1 or HDAC2 in mouse 
embryonic fibroblast (MEF) did not have any overt phenotype under normal growth 
condition, a double knockout MEF resulted in growth arrest and senescence (Wilting 
et al., 2010). The cell cycle analysis of these MEF showed that both HDAC1 and 2 
are needed for G1 to S phase transition. Deletion of both would lead to senescent-like 
G1 arrest. Thirdly, there is compensation mechanism between HDAC1 and HDAC2 
when one of them is being perturbed. When either HDAC1 or HDAC2 was depleted, 
the protein level of the other was found to be increased in murine tissues and cell lines 
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(Lagger et al., 2002; Senese et al., 2007). This change was observed in the protein 
level but not mRNA, suggesting that this reciprocal regulation may be occurring at the 
translational or post-translational level, possibly by modulating protein stability or 
protein-protein interaction. 
1.9.2 Distinct functions of HDAC1 and HDAC2 
Despite of their high homology, HDAC1 and 2 are not completely redundant. 
They have specific and different functions which cannot be replaced by the other. For 
example, overexpression of HDAC2 but not HDAC1 in neurons can reduce dendritic 
spine density and synapse number and plasticity (Guan et al., 2009). Also, knockdown 
of HDAC2, but not HDAC1, increased p27 in rat renal interstitial fibroblast NRK49F 
(Pang et al., 2011). Similarly, HDAC2, but not HDAC1, can inhibit proliferation and 
induce senescence in the breast cancer MCF7 cells (Harms and Chen, 2007). The 
same group also demonstrated that HDAC2 can modulate the ability of p53 to bind 
DNA, thus controlling the transcriptions of p53-dependent genes. On the other hand, 
the loss of HDAC1, but not HDAC2, can affect embryonic stem cells differentiation 
as HDAC1-deficient cells formed smaller embryoid bodies with preferential 
differentiation toward mesodermal and ectodermal lineages (Dovey et al., 2010). 
In fact, HDAC1 and 2 can have opposing effects. In mouse liver cells AML12, while 
silencing of HDAC1 can suppress TGFbeta1-induced apoptosis, silencing of HDAC2 
increased spontaneous apoptosis and enhanced transforming growth factor 
(TGF)beta1-induced apoptosis (Lei et al., 2010). This reciprocal effect on cell 
viability by HDAC1 and 2 is mediated through their differential regulation of 




1.10 Inhibition of HDAC 
In recent years, HDAC inhibition was recognized as a therapeutic strategy to 
treat various diseases by reversing the aberrant epigenetic state. These include 
treatment of neurodegenerative diseases (Selvi et al., 2010), acute pancreatitis 
(Escobar et al., 2010), and rheumatoid arthritis (Chung et al., 2003). Due to the 
effectiveness of HDAC inhibitors in killing tumor cells over normal cells, they have 
been most widely used in the treatment of various cancers. 
HDAC inhibitors include various classes of hydroxamic acids, electrophilic ketones, 
benzamides, cyclic peptides, short chain fatty acids, boronic acid-based compounds, 
benzofuranone and sulfonamide containing molecules (Marks, 2010b). Many of them 
have similar structural characteristics, such as the zinc-binding moiety in the catalytic 
pocket, opposite capping group and a straight chain alkyl, vinyl, or aryl linker that 
connects the two. HDAC inhibitors work by having these functional groups interact 
with the relatively conserved regions of HDAC (Finnin et al., 1999) 
 
1.11 Biological effects and mechanisms of action of HDAC inhibitors 
There are many biological effects of HDAC inhibitors that make them 
effective therapeutic agents against cancer. 
1.11.1 Apoptosis 
1.11.1.1  Intrinsic pathway 
Numerous studies demonstrated the involvement of the intrinsic or 
mitochondrial apoptotic pathway in HDAC inhibitor-induced cell death. For example, 
the overexpression of the anti-apoptotic proteins B-cell lymphoma-2 (BCL-2) and B-
cell lymphoma-extra large (BCL-XL), both of which are essential in the 
mitochondrial pathway, blocked suberoylanilide hydroxamic acid (SAHA)-induced 
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apoptosis in vitro (Vrana et al., 1999). Similarly, in vivo studies using a syngeneic 
mouse model of Burkitt’s lymphoma showed that primary B-cell lymphoma that 
overexpressed BCL-2 was resistant to SAHA, suggesting that activation of the 
mitochondrial pathway is required (Bolden et al., 2006).  
It is not fully understood how HDAC inhibitors activate the mitochondrial 
apoptotic pathway. One possibility is that they change the balance in the expression of 
pro-apoptotic and anti-apoptotic proteins, or there can also be activation of proteins or 
pathways upstream of the mitochondrial pathway. Examples of such proteins are the 
BH3-only proteins Bid, Bim, and Bmf. Bid was shown to be cleaved and activated 
upon HDAC inhibition (Ruefli et al., 2001). Bim was upregulated transcriptionally 
after treatment by SAHA and TSA and promoted apoptosis (Zhao et al., 2005). Bmf 
was transcriptionally activated by HDAC inhibitors depsipeptide and m-carboxy 
cinnamic acid bishydroxamic acid (CBHA), while knocking Bmf down can block 
mitochondrial membrane damage and partly rescue clonogenic potential of cells 
treated by these HDAC inhibitors (Zhang et al., 2006).  
In addition, the regulation of reactive oxygen species (ROS) production or 
activity can also mediate HDAC inhibition-induced activation of the mitochondrial 
apoptotic pathway. ROS is a natural byproduct of normal oxygen metabolism and 
play important roles in cell signaling. Their level can increase in the presence of 
environmental stress. HDAC inhibitor can promote the accumulation of ROS in tumor 
cells while treatment of free-radical scavengers can reduce the HDAC inhibition-
induced apoptosis (Ruefli et al., 2001). Interesting, ROS production can also 
transcriptionally induce and activate Bim, linking it to the involvement of the BH3-
only protein (Sade and Sarin, 2004). 
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1.11.1.2 Extrinsic pathway 
Other than the intrinsic pathway, HDAC inhibition can also cause cell death 
via the extrinsic (death-receptor) apoptotic pathway. Upon HDAC inhibitor treatment, 
many tumor necrosis factor (TNF) receptor superfamily members and their ligands, 
such as TNF-related apoptosis-inducing ligand (TRAIL), death receptor 5 (DR5), Fas, 
and TNF-alpha were found to be transcriptionally activated (Johnstone, 2002). 
Blocking the death-receptor signaling pathway can abrogate HDAC inhibitor-induced 
apoptosis. For example, in an in vivo study using the PML-RAR transgenic mice that 
develop acute myeloid leukemia (AML), it was shown that the suppression of TRAIL 
and Fas using siRNA can reduce valproic acid (VPA)-induced apoptosis by 50%  
(Insinga et al., 2005).  
1.11.2 Growth arrest 
Most of the HDAC inhibitors, except tubacin, can induce cell cycle arrest at 
the G1 to S phase boundary (Haggarty et al., 2003). This is mediated by the 
retinoblastoma protein (pRb) and related proteins.  Treatment with HDAC inhibitors 
leads to p53-independent induction of CDKN1A which encodes for p21 protein that 
promotes hypophosphorylation of pRb leading to cell cycle arrest (Richon et al., 
2000). Also, HDAC inhibition-induced repression of cyclin A and cyclin D 
contributes to the loss of CDK 4 and CDK2 kinase activities as well as 
hypophosphorylation of pRb (Sandor et al., 2000). In addition, HDAC inhibition 
transcriptionally represses CTP synthase and thymidylate synthetase which are 
involved in DNA synthesis (Glaser et al., 2003). The direct effect of chromatin 
remodeling and the subsequent changes in gene expression can induce cell-cycle 
regulatory genes such as GADD45 and cause the upregulation of TGFbeta receptor 
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signaling which represses c-MYC, leading to cell cycle arrest (Chen et al., 2002; 
Jaboin et al., 2002).  
Other than arresting cells at the G1/S phase, HDAC inhibition can mediate 
G2/M-phase arrest by activation of the G2-phase checkpoint. This, however, is not as 
common as the G1 arrest. It was proposed that while low concentration of HDAC 
inhibitors induces G1 arrest, higher concentration can induce both G1 and G2/M 
arrest (Richon et al., 2000). It is not fully understood how HDAC inhibition leads to 
G2 arrest. One possible mechanism could be the hyperacetylation of pericentric 
heterochromatin and the loss of the checkpoint would cause abnormal chromosomal 
segregation and nuclear fragmentation (Taddei et al., 2005). Because most tumor cells 
have defective G2 checkpoint, the HDAC inhibitor treated cells would accumulate in 
the G2/M phase and eventually pass this G2 checkpoint to undergo apoptosis (Peart et 
al., 2003). On the other hand, normal cells with a functional G2 checkpoint would be 
resistant to HDAC inhibition-induced apoptosis (Johnstone, 2002). This explains the 
differential effects of HDAC inhibitors on normal and tumor cells. Such tumor-
selective killing of HDAC inhibitors makes them a favorable strategy in cancer 
therapy.  
1.11.3 Mitotic disruption and autophagy 
HDAC inhibition can cause mitotic defects due to aberrant histone acetylation 
in the heterochromatin and centromere domains (Xu et al., 2007). Histone acetylation 
can interfere with histone phosphorylation, thereby disrupting the function of mitotic 
spindle checkpoint proteins (Dowling et al., 2005). This results in transient arrest at 
prometaphase, and eventually aberrant mitosis such as missegregation and loss of 
chromosomes occurs (Qiu et al., 2000). In colon cancer cell lines, HDAC inhibitor 
can induce polyploidy and mitotic defects, leading to senescence (Xu et al., 2005). 
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In an experimental model using cervical cancer cell line HeLa, it was demonstrated 
that HDAC inhibitors can still induce cell death even when caspase activation was 
blocked by overexpression of Bcl-XL (Shao et al., 2004). Instead of undergoing 
apoptosis, these cells showed morphology typical of autophagic cell death. 
1.11.4 Anti-angiogenesis, anti-metastasis and invasion 
Angiogenesis is a process that involves the growth of new blood vessels to 
supply the metabolic needs of the growing tumor. Hypoxia inducible factors (HIF) are 
transcription factors for angiogenic genes (Brown and Wilson, 2004). Under hypoxic 
conditions, class I  HDAC1, 2, and 3 are all activated in transformed cells, thus 
downregulating p53 and von Hippel–Lindau protein (pVHL), resulting in 
downregulation of factors inhibiting HIF (FIH) (Liang et al., 2006). This leads to 
activation of HIF-1alpha and angiogenesis. HDAC inhibition can prevent this tumor 
angiogenesis by inhibiting the HIF. Several HDAC inhibitors, such as TSA, vorinostat, 
FK228, butyrate and LAQ824 have been found to repress angiogenesis in vitro and in 
vivo, and downregulate pro-angiogenesis factors such as HIF-1alpha and vascular 
endothelial growth factor (VEGF) (Deroanne et al., 2002). In addition, HDAC 
inhibition was demonstrated to reduce expression of the chemokine (C-X-C motif) 
receptor 4 (CXCR4) (Crazzolara et al., 2002). This would prevent the homing of 
bone-marrow progenitor and circulating endothelial cells to the site of angiogenesis. 
Other than exerting its effects on the primary tumor, HDAC inhibition can 
also affect metastasis. Metastasis is the growth of tumor distant from the site of the 
primary tumor. It is a multi-step process that enables the tumor cells to overcome 
barriers to local invasion, intravasation, survive in circulation, extravasation and 
eventually outgrowth to produce marcrometastases at a distant site. Many proteins are 
involved in facilitating this process. For example, matrix metalloproteinases (MMPs) 
25 
 
can degrade the extracellular matrix to allow invasion and intravasation. HDAC 
inhibitors can transcriptionally repress MMPs such as MMP2 and MMP9 (Klisovic et 
al., 2003). Concurrently, there is upregulation of Reversion-inducing-cysteine-rich 
protein with kazal motifs (RECK) which is known to negatively regulate MMP, as 
well as upregulation of tissue inhibitor of metalloproteinase (TIMP) (Liu et al., 2003). 
In addition to these in vitro studies, there are in vivo studies to demonstrate the anti-
metastatic effect of HDAC inhibition. For example, using intrasplenic implant in mice 
model, treatment by HDAC inhibitor HA-butyrate can reduce incidence of metastasis 
and prolong survival (Coradini et al., 2004). 
1.11.5 Anti-tumor immunity 
There is a growing pool of evidence to show that HDAC inhibition can 
increase anti-tumor immunity by making the tumor cells more attractive immune 
targets, influencing immune cells activities, or by altering the production of cytokines 
(Bolden et al., 2006).  
HDAC inhibition can upregulate major histocompatibility complex (MHC) 
class I and II proteins, and co-stimulatory/adhesion molecules and intracellular 
adhesion molecule 1 (ICAM1) (Maeda et al., 2000; Magner et al., 2000). In addition, 
HDAC inhibition induces MHC class I chain-related molecules MICA and MICB on 
the tumor cell surface. These molecules bind to the activating immunoreceptor natural 
killer cell protein group (NKG)2D on the cell surface of natural killer cells, γδ T cells 
and CD8 T cells. Tumor cells that express MICA and MICB on their surface are 
targets for NKG2D-restricted cytotoxicity. Upon treatment by HDAC inhibitor, HCC 
cells but not normal hepatocytes, have upregulated MICA and MICB and were killed 
by natural killer cells (Armeanu et al., 2005). 
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Signal transducer and activator of transcription 1 (STAT1), STAT3, and nuclear 
factor-κB (NF-κB) are considered as “master immune regulatory transcription factors” 
and their gene regulatory activities are regulated by acetylation (Chen et al., 2001; 
Nusinzon and Horvath, 2003; Yuan et al., 2005). It is possible that changes in 
cytokine profiles and their effects on immune cell functions after HDAC inhibition 
may be mediated through these transcriptional factors.  
 
1.12   HDAC inhibitors in cancer therapy 
1.12.1 Clinical trials 
There are currently many HDAC inhibitors that are undergoing various phases 
of clinical trials for different types of cancer (Table 1.1) 




identifiers Clinical trial phase 
Valprioc Acid Depakene 
Phase I/II in hematological 
malignancies and solid tumors; 
FDA-approved for epilepsy, 
seizures, bipolar disorder 
Vorinostat 
Suberoylanilide 
hydroxamic acid (SAHA), 
Zolinza 
Phase I/II in hematological 
malignancies and solid tumors; 
FDA-approved for CTCL 
Panobinostat LBH589 
Phase I/II in hematological 
malignancies and solid tumor 
Belinostat PXD101 
Phase I/II in hematological 
malignancies and solid tumor 
Entinostat MS-275 
Phase I/II in hematological 
malignancies and solid tumor 
MGD0103 Mocetinostat 
Phase I/II in hematological 




Phase I/II in hematological 
malignancies and solid tumor, 
FDA-approved for CTCL 
Givinostat ITF-2357 
Phase I/II in hematological 
malignancies and solid tumor 
PCI-24781 CRA-2024781 Phase I 




Of these, Vorinostat (SAHA) was approved by the United States of America Food and 
Drug Administration (FDA) in 2006 for the treatment of refractory cutaneous T-cell 
lymphoma (CTCL) (Marks and Breslow, 2007). A multicenter phase IIb trial tested 
the drug on 74 patients with CTCL who had at least 2 prior therapies. They were 
given daily dose of 400mg of Vorinostat orally and have an overall response rate of 
29.7%, a 6.1 months median duration of response, and a 9.8 months median time to 
progression (Olsen et al., 2007). The side effects included diarrhea, fatigue, nausea, 
thrombocytopenia and anemia. Vorinostat was also tested in other malignancies such 
as relapsed diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), 
platinum-resistant epithelial ovarian cancer, primary peritoneal carcinoma, and non-
small cell lung carcinoma (NSCLC) (Crump et al., 2008; Ramalingam et al., 2007).  
Another drug approved by the FDA is Romidepsin (desipeptide) and it is also for 
treatment of CTCL (Federico and Bagella, 2011). Romidepsin is a natural compound 
isolated from Chromobacterium violaceum. It was first tested for its antibacterial 
activity but was found to exhibit cytotoxicity on tumor cells. The main targets of this 
drug are class I HDACs. The 2 phase II multicenter clinical trials recruited a total of 
167 patients with refractory CTCL. The median time to response was 2 months with 
an overall response rate of about 34%. Side effects of the drug include nausea, fatigue, 
vomiting, anorexia, and cardiotoxicity. Other than CTCL, desipeptide was also tested 
in AML, chronic lymphocytic leukemia (CLL), lung cancer, hormone refractory 
prostate cancer, and renal cancer (Byrd et al., 2005; Fouladi et al., 2006; Schrump et 
al., 2008).  
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1.12.2 Synergism with other anti-cancer treatments 
1.12.2.1 Drugs 
In addition to being used as a single agent to treat various types of cancers, 
HDAC inhibitors have also shown synergism with other drugs in killing tumor cells. 
These include proteasome inhibitor bortezomib, Bcr-Abl kinase inhibitor, imatinib, 
cyclin-dependent kinase inhibitor flavopiridol, IkBa phosphorylation inhibitor BAY 
11-7082 and many others (Jagannath et al., 2010; Marks, 2010a). 
The rationale behind the choice of drug combination is usually based on the 
molecular mechanisms by which the drugs work. For example, tumor suppressor 
genes are most effectively reactivated by sequential DNA demethylation followed by 
histone acetylation (Cameron et al., 1999). This provided the basis for the use of 
demethylating agent such as 5-aza-cytidine with HDAC inhibitors. This treatment 
regime was tested clinically for patients with myelodysplastic syndrome and AML. 
Partial and complete responses have been reported with reactivation of genes such as 
CDKN1A (encoding p21 protein) (Gore et al., 2006). 
HDAC inhibitors can also be used together with other conventional 
chemotherapeutic drugs to augment their effects. For example, a standard drug for 
relapsing myeloma, dexamethasone, was shown to be synergistic with the HDAC 
inhibitor LAQ824 due to enhanced apoptotic signaling (Catley et al., 2003; Chauhan 
et al., 2001). Dexamethasone induces the release of second mitochondria-derived 
activator of caspases (SMAC) from the mitochondria into the cytosol, leading to 
neutralization of the inhibitory effects of inhibitor of apoptosis (IAPs) on caspase 9. 
This enhances the caspase 9-mediated cytotoxic effects of LAQ824. Concurrently, 
LAQ824 activates caspase 8 which serves as an additional apoptotic signal to that 




Many HDAC inhibitors have been shown to act synergistically with γ-
irradiation to kill tumor cells in vitro (Kim et al., 2004; Zhang et al., 2004). There 
were also further studies in animal models to show similar results. For example, using 
the DU145 prostate carcinoma xenograft, a combination of radiation and HDAC 
inhibitor MS-275 resulted in histone hyperacetylation and greater inhibition of tumor 
growth compared to single treatment (Camphausen et al., 2004). Similarly, HDAC 
inhibitor Valproic acid can radiosensitize the human brain tumor cell line U251 in 
mice xenograft model, resulting in delayed tumor growth (Camphausen et al., 2005). 
Ataxia telangiectasia mutated (ATM) is a serine/threonine protein kinase activated by 
double-strand break damage to DNA, and can activate downstream targets to mediate 
biological response to DNA damage such as apoptosis (Shiloh, 2003). HDAC 
inhibition can activate ATM even in the absence of DNA double-strand breaks 
(Bakkenist and Kastan, 2003). Moreover, HDAC inhibition can suppress DNA repair 
with downregulated expression of DNA repair proteins Ku70, Ku86 and DNA protein 
kinase (Munshi et al., 2005). The activation of ATM as well as the suppression of 
DNA repair may explain how HDAC inhibition acts synergistically with radiation 
therapy to kill tumor cells.  
In addition, HDAC inhibitors were shown to decrease cutaneous radiation 
syndrome (CRS), which is skin-morbidity caused by radiation. HDAC inhibitors, such 
as Valproic acid, can promote healing of radiation-induced wounds and decrease skin 
fibrosis (Chung et al., 2004). Therefore, HDAC inhibitors greatly increase the 
therapeutic gain in cancer radiotherapy by enhancing the inhibition of tumor growth 











 CHAPTER 2 AIMS 
 
Histone deacetylase (HDAC) inhibitors are gaining ground as a new class of 
chemotherapeutic agent in recent years. Much effort has been put into the 
development of new HDAC inhibitors that are more isoforms-specific, in hope of 
reducing off-target effects associated with drug used. To effectively design and utilize 
HDAC inhibitors in the treatment of cancer, we need to better understand the 
functions of the HDAC isoforms and their mechanism of actions. Numerous studies 
tried to test the effect of knocking down each individual isoform of HDAC on gene 
expressions and survival in cancer cells. However, the results vary between different 
tissues and contexts. We seek to study the expression, functions, and mechanism of 
action of 2 highly homologous histone deacetylases, HDAC1 and 2, in hepatocellular 
carcinoma (HCC).  
The first step to understanding the role of a protein in the development and 
progression of cancer is to compare its expression in the tumor to that in the normal 
tissue. To establish the clinical significance of HDAC1 and 2 in HCC, we will study 
the expression of HDAC1 and HDAC2 in human HCC samples and correlate their 
expression with clinicopathological parameters such as patient survival. This will 
establish the clinical significance of HDAC1 and 2 in HCC. Secondly, we will study 
the individual and cooperative roles of HDAC1 and 2 in HCC cell lines. We will 
focus specifically on cell survival and proliferation, which are critical characteristics 
of tumor cells that chemotherapy targets. This would be done by measuring the ability 
of the cells to form colonies, as well as the cell cycle profiles. Thirdly, the mechanism 
by which HDAC1 and 2 exert their effects on the cells would be examined. We will 
test if the functions of HDAC1 and 2 are dependent on their enzymatic activity. Lastly, 
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we will study the gene targets of HDAC1 and 2 and validate their roles in mediating 
the effects of HDAC1 and 2 in cell survival and proliferation. 
This study would shed light on the roles of the 2 important members of the 













 CHAPTER 3 MATERIALS & METHODS 
 
3.1 Tissue Microarray 
3.1.1 Tissue Samples 
A total of 358 hepatocellular carcinoma samples (179 sets of tumor and paired 
non-tumor) were included in this study. These were obtained from the Department of 
Pathology, National University Hospital of Singapore. There was no selection bias 
regarding gender, age, clinical presentation or tumor staging. Morphologically 
representative area of the tumor was annotated by the pathologist and 1.5mm tissue 
cylinders were punched from the donor tissue block and deposited into a recipient 
block using the Advanced Tissue Arrayer (Chemicon International, USA). The 
recipient tissue block was cut using a microtome into sections and placed onto a 
coated glass slide for immunohistochemical staining. 
3.1.2 Immunohistochemistry 
Tissue sections were deparaffinized in xylene and rehydrated in serial alcohol 
dilutions. Antigen retrieval was performed by heating the sections in Antigen 
Unmasking Solution (Vector Laboratory, USA)  for 20 min using the microwave 
oven.  The sections were then treated with 3% H2O2 to remove endogenous 
peroxidase activity, washed in PBST, and incubated with primary antibodies 
overnight at 4C with gentle shaking. After optimization was performed to obtain 
optimal staining intensity, rabbit polyclonal antibody against HDAC1 from Abcam 
was used at 1:8000 dilution, while rabbit polyclonal antibody against HDAC2 from 




After the sections were washed 3 times in PBST for 5 mins each, they were 
incubated with secondary antibody, which is a goat anti-rabbit IgG conjugated with 
avidin-biotinylated horseradish peroxidase (DAKO, Glostrup, Denmark). Lastly, the 
sections were washed 3 times in PBST for 5 mins each and incubated for 1 min with 
DAB substrate. Counterstaining was done using Hematoxylin solution (Sigma) and 
the sections were then dehydrated in serial alcohol dilution and mounted with 
coverslips. 
3.1.3 Scoring of Tissue Microarray 
Each sample on the tissue microarray slides was scored based on the intensity 
of staining in the nuclei of the hepatocytes. Whenever staining was observed, it was 
almost always limited to the nucleus and not the cytoplasm. A score of 0 indicated no 
nuclear staining while a score of 1, 2 and 3 represented low, moderate, and intense 
nuclear staining respectively. To obtain an index to whether the HDAC expression is 
upregulated, the score of the non-tumor sample was subtracted from that of the 
matched tumor sample (T-N). A positive index (T-N>0) would indicate that HDAC 
expression was upregulated in the tumor for that sample pair, a negative index (T-
N<0) would indicate that HDAC expression was downregulated in the tumor for that 
sample pair, while an index of 0 would indicate that HDAC expression was not 
changed for that sample pair.  
3.1.4 Statistical analysis 
Statistical analysis was performed using SPSS. Survival rates of patients with 
different HDAC1 and HDAC2 expression levels were analyzed using Kaplan-Meier 




3.2 Cell lines and cell culture 
3.2.1 Cell lines 
The human colon cancer cell lines, HCT116 and HT29, human 
hepatocarcinoma cell lines, HEP3B, HEPG2 and PLC5, were purchased from 
American Type Culture Collection (Rockville, MD). The HCT116 p53-/- cells were a 
kind gift from Dr. Vogelstein’s lab at Johns Hopkins University (Baltimore, MD). 
The HCT116 and HT29 cells were cultured in McCoy’s 5A (Sigma) medium 
supplemented with 10% fetal bovine serum (Gibco). The HEP3B, HEPG2 and PLC5 
cells were cultured in DMEM (Sigma) medium supplemented with 10% fetal bovine 
serum (Gibco). The cells were maintained in an incubator at 37C in a 5% CO2 
humidified atmosphere.  
3.2.2 Transient transfection 
Twenty-four hours before transfection, the cells were counted using a 
hemocytometer and plated at a density such that they would be about 40% confluent 
on the day of transfection.  
For the overexpression of plasmid, 1g of plasmid DNA or empty vector 
control was diluted in 125l of Opti-MEM medium (Gibco), which was added to 5l 
of Lipofectamine2000 Reagent (Invitrogen) that had been diluted in 125l of Opti-
MEM medium. The mixture was incubated at room temperature for 20-30 min before 
it was added dropwise to the cells plated in a 6-well plate with 750l of Opti-MEM 
medium. The plate was incubated at 37C in a 5% CO2 humidified atmosphere for 4-5 
hours before the Opti-MEM medium was replaced with the usual media in which the 
cells were normally cultured. 
For the knockdown of genes, 20pmol of siRNA (Invitrogen) or universal 
control siRNA with matching  %GC content was diluted in 250l of Opti-MEM 
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medium (Gibco), which was added to 3l of Lipofectamine RNAiMax Reagent 
(Invitrogen) that had been diluted in 250l of Opti-MEM medium. The mixture was 
incubated at room temperature for 10-20 min before it was added dropwise to the cells 
plated in a 6-well plate with 500l of Opti-MEM medium. The plate was incubated at 
37C in a 5% CO2 humidified atmosphere for 4-5 hours before the Opti-MEM 
medium was replaced with the usual media in which the cells were normally cultured.  
 
3.3 Western Blot 
3.3.1 Protein extraction 
Cells were washed in 1X PBS and collected by trypsinization and pelleted at 
1000 RPM for 5 min at 4C. The cell pellet was washed in cold 1X PBS and stored in 
-80C until protein extraction. 
Total protein extraction was performed by adding 50-100l lysis buffer (6M 
urea, 1% 2-mercaptoethanol, 50mM Tris buffer pH 7.4, 1% SDS in PBS pH 7.4) to 
the cell pellet. To lyse the cells, sonication was done at 20kHz for 3 pulses of 15 sec 
each with the 2mm microtip probe using the High Intensity Ultrasonic Processor 
130W model (SciMed).  
Frozen normal liver was obtained from Department of Pathology, National 
University of Singapore. It was taken from a patient who has colorectal cancer with 
liver metastases and was undergoing surgery. The frozen tissue was weighed, 
homogenized with 3 volume of lysis buffer in a glass homogenizer, and sonicated as 
described above. After centrifugation at 13,000 RPM for 15 min at 40C, the 
supernatant was collected as protein lysate. 
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3.3.2 Protein quantification 
The samples were quantified using the BioRad Protein Assay Kit (BioRad) 
with bovine serum albumin (Sigma) as the standard. The reagent was diluted 5X with 
distilled water before use. Each sample was serially diluted between 20X to 40X and 
10l of each diluted sample was added to a well in a 96well plate, in duplicates. Two 
hundred l of diluted reagent was added to each well and incubated at room 
temperature for 5 min before reading the absorbance at 595nm using the 
spectrophotometer. The protein concentration would be calculated using the standard 
curve generated by the BSA standards of known concentrations. 
3.3.3 SDS PAGE and transfer 
Ten to 20g of each sample was mixed with 5X loading buffer (10% SDS, 
50% glycerol, 0.01% bromophenol blue, 7% DTT, 50mM Tris pH 6.8), heated at 
95C for 4 min and ran in a 4% stacking/10-12% resolving polyacrylamide gel in 
Glycine running buffer (0.1% SDS, 14.4mg/ml Glycine, 3.03mg/ml Tris) at 130V for 
1 hour. A prestained protein ladder (BioRad) was run alongside as a marker for the 
molecular weight. After electrophoresis, the gel was equilibrated in transfer buffer 
(20% ethanol, 0.1% SDS, 14.4mg/ml Glycine, 3.03mg/ml Tris) for 15 min before 
being set up for transfer onto nitrocellulose membrane (Hybond C-Extra, 0.45 m, 
Amersham Biosciences) at 100V for 1.5 hours.  
3.3.4 Immunodetection 
Nitrocellulose membrane was blocked in 5% non-fat milk (Anlene) in PBST 
(1X PBS, 0.1% Tween-20) for 1 hour at room temperature on a shaker. After 
blocking, the membrane was incubated in primary antibody diluted in 3% non-fat 
milk in PBST for 1 to 2 hours at room temperature. The membrane was then washed 
in PBST for 5 min thrice, and incubated with the corresponding secondary antibody 
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(anti-mouse, or anti-rabbit, or anti-goat) conjugated to horseradish peroxidase (HRP) 
diluted 5000X to 10000X in PBST, for 1 to 2 hours at room temperature. All the 
secondary antibodies used were from Santa Cruz Biotechnology. The blots were then 
washed again in PBST thrice and incubated with Western Lightning Plus ECL reagent 
(Perkin Elmer) for 1min at room temperature. The membrane was exposed at Kodak 
Biomax MS film (Kodak) for 30 sec to 15 min depending on the intensity of the 
signal, and the films were developed in the Kodak X-ray Processor. 
3.3.5 Antibodies 
Table 3.1 List of antibodies used in western blot. 
Antibody Company Source Dilution 
HDAC1 Upstate Mouse monoclonal 1:1,000 
HDAC2 Upstate Mouse monoclonal 1:1,000 
GAPDH Santa Cruz Mouse monoclonal 1:5,000 
Actin Sigma Mouse monoclonal 1:10,000 
Caspase 3 Cell Signaling Mouse monoclonal 1:1,000 
PARP Cell Signaling Rabbit polyclonal 1:1,000 
P53 Santa Cruz Mouse monoclonal 1:2,000 
P21 Santa Cruz Mouse monoclonal 1:500 
NMES Santa Cruz Rabbit Polyclonal 1:500 
CYGB Santa Cruz Rabbit Polyclonal 1:500 
MAGEC2 Santa Cruz Goat Polyclonal 1:500 
PLCgamma2 Santa Cruz Rabbit Polyclonal 1:500 
LOX Abcam Rabbit Polyclonal 1:1000 
LOXL4 Abcam Rabbit Polyclonal 1:1000 
GalR2 Abcam Rabbit Polyclonal 1:500 
 
3.3.6 Densitometry  
To quantify the Western Blot results, the GS800 Calibrated Densitometer 
(BioRad) was used to scan the films after developing. A software (QuantityOne) was 




3.4 Design of siRNA to knockdown HDAC1 and 2 
Both HDAC1 and HDAC2 belong to class I of mammalian HDAC and are 
highly homologous. Their mRNA coding sequence shared 74.3% identity upon 
alignment (Figure 3.1). Stealth RNAi siRNA was purchased from Invitrogen (Life 
Technologies, USA). Three siRNA sequences (A, B and C) each targeting different 
regions along the mRNAs of HDAC1 and HDAC2 were shown in Figure 3.2 and 
Figure 3.3 respectively. A universal non-silencing control (Scr) that has sequences of 




































EMBOSS_001         1 atggcg--cagacgcag-ggcacccggaggaaagtctgttactactacga     47 
                     ||||||  |||.|...| |||..|...|..||||||||.||||||||||| 
EMBOSS_001         1 atggcgtacagtcaaggaggcggcaaaaaaaaagtctgctactactacga     50 
EMBOSS_001        48 cggggatgttggaaattactattatggacaaggccacccaatgaagcctc     97 
                     |||.|||.||||||||||.|||||||||||.||.||.||.|||||||||| 
EMBOSS_001        51 cggtgatattggaaattattattatggacagggtcatcccatgaagcctc    100 
EMBOSS_001        98 accgaatccgcatgactcataatttgctgctcaactatggtctctaccga    147 
                     |..|||||||||||||.|||||.||||||.|.||.|||||..|.|||.|| 
EMBOSS_001       101 atagaatccgcatgacccataacttgctgttaaattatggcttatacaga    150 
EMBOSS_001       148 aaaatggaaatctatcgccctcacaaagccaatgctgaggagatgaccaa    197 
                     |||||||||||.|||.|.||.||.|||||||.|||.||.||.|||||.|| 
EMBOSS_001       151 aaaatggaaatatataggccccataaagccactgccgaagaaatgacaaa    200 
EMBOSS_001       198 gtaccacagcgatgactacattaaattcttgcgctccatccgtccagata    247 
                     .||.|||||.|||||.||.||.|||||..|.||.||.||..|.||||||| 
EMBOSS_001       201 atatcacagtgatgagtatatcaaatttctacggtcaataagaccagata    250 
EMBOSS_001       248 acatgtcggagtacagcaagcagatgcagagattcaacgttggtgaggac    297 
                     |||||||.|||||.||.|||||||||||.|.|||.||.|||||.||.||. 
EMBOSS_001       251 acatgtctgagtatagtaagcagatgcatatatttaatgttggagaagat    300 
EMBOSS_001       298 tgtccagtattcgatggcctgtttgagttctgtcagttgtctactggtgg    347 
                     |||||||..||.|||||.||.||||||||.||||||.|.||.|||||.|| 
EMBOSS_001       301 tgtccagcgtttgatggactctttgagttttgtcagctctcaactggcgg    350 
EMBOSS_001       348 ttctgtggcaagtgctgtgaaacttaataagcagcagacggacatcgctg    397 
                     |||.||.||..|.||||||||..|.||....||.|||||.||.||.|||| 
EMBOSS_001       351 ttcagttgctggagctgtgaagttaaaccgacaacagactgatatggctg    400 
EMBOSS_001       398 tgaattgggctgggggcctgcaccatgcaaagaagtccgaggcatctggc    447 
                     |.|||||||||||.||..|.||.|||||.|||||.|.|||.|||||.||. 
EMBOSS_001       401 ttaattgggctggaggattacatcatgctaagaaatacgaagcatcagga    450 
EMBOSS_001       448 ttctgttacgtcaatgatatcgtcttggccatcctggaactgctaaagta    497 
                     |||||||||||.||||||||.||..|.||||||||.|||.|.|||||||| 
EMBOSS_001       451 ttctgttacgttaatgatattgtgcttgccatccttgaattactaaagta    500 
EMBOSS_001       498 tcaccagagggtgctgtacattgacattgatattcaccatggtgacggcg    547 
                     |||.|||||.||..|.||.|||||.||.||||||||.||||||||.||.| 
EMBOSS_001       501 tcatcagagagtcttatatattgatatagatattcatcatggtgatggtg    550 
EMBOSS_001       548 tggaagaggccttctacaccacggaccgggtcatgactgtgtcctttcat    597 
                     |.|||||.||.||.||.||.||.||.||.||.|||||.||.||.||.||| 
EMBOSS_001       551 ttgaagaagctttttatacaacagatcgtgtaatgacggtatcattccat    600 
EMBOSS_001       598 aagtatggagagtacttcccaggaactggggacctacgggatatcggggc    647 
                     ||.|||||.||.|||||.||.||.||.||.|||.|..|||||||.||.|| 
EMBOSS_001       601 aaatatggggaatactttcctggcacaggagacttgagggatattggtgc    650 
EMBOSS_001       648 tggcaaaggcaagtattatgctgttaactacccgctccgagacgggattg    697 
                     |||.||||||||.||.||||||||.||.|..||..|..|.||.||.||.| 
EMBOSS_001       651 tggaaaaggcaaatactatgctgtcaattttccaatgtgtgatggtatag    700 
EMBOSS_001       698 atgacgagtcctatgaggcc-attttcaagccggtcatgtccaaagtaat    746 
                     ||||.|||||.|||| |||. ||.||.|||||..|.||.||.||.||.|| 
EMBOSS_001       701 atgatgagtcatatg-ggcagatatttaagcctattatctcaaaggtgat    749 
EMBOSS_001       747 ggagatgttccagcctagtgcggtggtcttacagtgtggctcagactccc    796 
                     ||||||||..||.||||||||.|||||.|||||||||||..|||||||.. 





EMBOSS_001       797 tatctggggatcggttaggttgcttcaatctaactatcaaaggacacgcc    846 
                     |||||||.|||.|..|.|||||.|||||||||||..|||||||.||.||. 
EMBOSS_001       800 tatctggtgatagactgggttgtttcaatctaacagtcaaaggtcatgct    849 
EMBOSS_001       847 aagtgtgtggaatttgtcaagagctttaacctgcctatgctgatgctggg    896 
                     ||.|||||.|||.||||.||.|..||||||.|.||..|.||||||||.|| 
EMBOSS_001       850 aaatgtgtagaagttgtaaaaacttttaacttaccattactgatgcttgg    899 
EMBOSS_001       897 aggcggtggttacaccattcgtaacgttgcccggtgctggacatatgaga    946 
                     |||.|||||.|||||.||.|||||.|||||.||.||.||||||||||||| 
EMBOSS_001       900 aggaggtggctacacaatccgtaatgttgctcgatgttggacatatgaga    949 
EMBOSS_001       947 cagctgtggccctggatacggagatccctaatgagcttccatacaatgac    996 
                     |.||.||.|||||.|||...|||||.||.||||||.|.|||||.|||||. 
EMBOSS_001       950 ctgcagttgcccttgattgtgagattcccaatgagttgccatataatgat    999 
EMBOSS_001       997 tactttgaatactttggaccagatttcaagctccacatcagtccttccaa   1046 
                     ||||||||.||.|||||||||||.|||||.||.||.||.||||||||.|| 
EMBOSS_001      1000 tactttgagtattttggaccagacttcaaactgcatattagtccttcaaa   1049 
EMBOSS_001      1047 tatgactaaccagaacacgaatgagtacctggagaagatcaaacagcgac   1096 
                     .|||||.|||||||||||....||.||..||||.|||||.||||||||.. 
EMBOSS_001      1050 catgacaaaccagaacactccagaatatatggaaaagataaaacagcgtt   1099 
EMBOSS_001      1097 tgtttgagaaccttagaatgctgccgcacgcacctggggtccaaatgcag   1146 
                     |||||||.||..|..|.|||.|.||.||.||||||||.|||||.|||||. 
EMBOSS_001      1100 tgtttgaaaatttgcgcatgttacctcatgcacctggtgtccagatgcaa   1149 
EMBOSS_001      1147 gcgattcctgaggacgccatccctgaggagagtggcgatgaggacgaaga   1196 
                     ||.|||||.||.||.||..|.|.|||.||.|||||.|||||.||.|.||| 
EMBOSS_001      1150 gctattccagaagatgctgttcatgaagacagtggagatgaagatggaga   1199 
EMBOSS_001      1197 cgaccctgacaagcgcatctcgatctgctcctctgacaaacgaattgcct   1246 
                     .||.||.||||||.|.||.||.||..|..|.||.|||||.||.||.||.| 
EMBOSS_001      1200 agatccagacaagagaatttctattcgagcatcagacaagcggatagctt   1249 
EMBOSS_001      1247 gtgaggaagagttctccgattctgaagaggagggagaggggggccgcaag   1296 
                     ||||.|||||.|||||.||||||||.||.||.|||||.||.||.|| ||| 
EMBOSS_001      1250 gtgatgaagaattctcagattctgaggatgaaggagaaggaggtcg-aag   1298 
EMBOSS_001      1297 aactcttcc--aacttcaaaaa--agccaagagagtcaaaacagaggatg   1342 
                     ||.|.|..|  |.|.|.|.|||  |||.||||.||..|.||..||.||.| 
EMBOSS_001      1299 aaatgtggctgatcataagaaaggagcaaagaaagctagaattgaagaag   1348 
EMBOSS_001      1343 aaaaagagaaagacccagaggagaagaa---agaagtcaccgaagaggag   1389 
                     |.|   |||||||..|||||||.||.||   |||.||.|..|||||.||. 
EMBOSS_001      1349 ata---agaaagaaacagaggacaaaaaaacagacgttaaggaagaagat   1395 
EMBOSS_001      1390 aaaaccaagga-------ggag--aagccagaagccaaaggggtcaa---   1427 
                     |||.|||||||       ||.|  ||..||||..|||||||...|||    
EMBOSS_001      1396 aaatccaaggacaacagtggtgaaaaaacagataccaaaggaaccaaatc   1445 
EMBOSS_001      1428 ggaggaggtcaagttggcctga   1449 
                     .||..||.|||......||||| 
EMBOSS_001      1446 agaacagctcagcaacccctga   1467 







        1 gagcggagcc gcgggcggga gggcggacgg accgactgac ggtagggacg ggaggcgagc 
       61 aagatggcgc agacgcaggg cacccggagg aaagtctgtt actactacga cggggatgtt 
      121 ggaaattact attatggaca aggccaccca atgaagcctc accgaatccg catgactcat 
      181 aatttgctgc tcaactatgg tctctaccga aaaatggaaa tctatcgccc tcacaaagcc 
      241 aatgctgagg agatgaccaa gtaccacagc gatgactaca ttaaattctt gcgctccatc 
      301 cgtccagata acatgtcgga gtacagcaag cagatgcaga gattcaacgt tggtgaggac 
      361 tgtccagtat tcgatggcct gtttgagttc tgtcagttgt ctactggtgg ttctgtggca 
      421 agtgctgtga aacttaataa gcagcagacg gacatcgctg tgaattgggc tgggggcctg 
      481 caccatgcaa agaagtccga ggcatctggc ttctgttacg tcaatgatat cgtcttggcc 
      541 atcctggaac tgctaaagta tcaccagagg gtgctgtaca ttgacattga tattcaccat 
      601 ggtgacggcg tggaagaggc cttctacacc acggaccggg tcatgactgt gtcctttcat 
      661 aagtatggag agtacttccc aggaactggg gacctacggg atatcggggc tggcaaaggc 
      721 aagtattatg ctgttaacta cccgctccga gacgggattg atgacgagtc ctatgaggcc 
      781 attttcaagc cggtcatgtc caaagtaatg gagatgttcc agcctagtgc ggtggtctta 
      841 cagtgtggct cagactccct atctggggat cggttaggtt gcttcaatct aactatcaaa 
      901 ggacacgcca agtgtgtgga atttgtcaag agctttaacc tgcctatgct gatgctggga 
      961 ggcggtggtt acaccattcg taacgttgcc cggtgctgga catatgagac agctgtggcc 
     1021 ctggatacgg agatccctaa tgagcttcca tacaatgact actttgaata ctttggacca 
     1081 gatttcaagc tccacatcag tccttccaat atgactaacc agaacacgaa tgagtacctg 
     1141 gagaagatca aacagcgact gtttgagaac cttagaatgc tgccgcacgc acctggggtc 
     1201 caaatgcagg cgattcctga ggacgccatc cctgaggaga gtggcgatga ggacgaagac 
     1261 gaccctgaca agcgcatctc gatctgctcc tctgacaaac gaattgcctg tgaggaagag 
     1321 ttctccgatt ctgaagagga gggagagggg ggccgcaaga actcttccaa cttcaaaaaa 
     1381 gccaagagag tcaaaacaga ggatgaaaaa gagaaagacc cagaggagaa gaaagaagtc 
     1441 accgaagagg agaaaaccaa ggaggagaag ccagaagcca aaggggtcaa ggaggaggtc 
     1501 aagttggcct gaatggacct ctccagctct ggcttcctgc tgagtccctc acgtttcttc 
     1561 cccaacccct cagattttat attttctatt tctctgtgta tttatataaa aatttattaa 
     1621 atataaatat ccccagggac agaaaccaag gccccgagct cagggcagct gtgctgggtg 
     1681 agctcttcca ggagccacct tgccacccat tcttcccgtt cttaactttg aaccataaag 
     1741 ggtgccaggt ctgggtgaaa gggatacttt tatgcaacca taagacaaac tcctgaaatg 
     1801 ccaagtgcct gcttagtagc tttggaaagg tgcccttatt gaacattcta gaaggggtgg 
     1861 ctgggtcttc aaggatctcc tgtttttttc aggctcctaa agtaacatca gccattttta 
     1921 gattggttct gttttcgtac cttcccactg gcctcaagtg agccaagaaa cactgcctgc 
     1981 cctctgtctg tcttctccta attctgcagg tggaggttgc tagtctagtt tcctttttga 
     2041 gatactattt tcatttttgt gagcctcttt gtaataaaat ggtacatttc t 
 
 
Figure 3.2  HDAC1 mRNA and location of siRNA sequences. Three siRNA 
sequences against HDAC1 (1A, 1B, and 1C) were purchased from Invitrogen and 







        1 cgccgagctt tcggcacctc tgccgggtgg taccgagcct tcccggcgcc ccctcctctc 
       61 ctcccaccgg cctgcccttc cccgcgggac tatcgccccc acgtttccct cagccctttt 
      121 ctctcccggc cgagccgcgg cggcagcagc agcagcagca gcagcaggag gaggagcccg 
      181 gtggcggcgg tggccgggga gcccatggcg tacagtcaag gaggcggcaa aaaaaaagtc 
      241 tgctactact acgacggtga tattggaaat tattattatg gacagggtca tcccatgaag 
      301 cctcatagaa tccgcatgac ccataacttg ctgttaaatt atggcttata cagaaaaatg 
      361 gaaatatata ggccccataa agccactgcc gaagaaatga caaaatatca cagtgatgag 
      421 tatatcaaat ttctacggtc aataagacca gataacatgt ctgagtatag taagcagatg 
      481 catatattta atgttggaga agattgtcca gcgtttgatg gactctttga gttttgtcag 
      541 ctctcaactg gcggttcagt tgctggagct gtgaagttaa accgacaaca gactgatatg 
      601 gctgttaatt gggctggagg attacatcat gctaagaaat acgaagcatc aggattctgt 
      661 tacgttaatg atattgtgct tgccatcctt gaattactaa agtatcatca gagagtctta 
      721 tatattgata tagatattca tcatggtgat ggtgttgaag aagcttttta tacaacagat 
      781 cgtgtaatga cggtatcatt ccataaatat ggggaatact ttcctggcac aggagacttg 
      841 agggatattg gtgctggaaa aggcaaatac tatgctgtca attttccaat gtgtgatggt 
      901 atagatgatg agtcatatgg gcagatattt aagcctatta tctcaaaggt gatggagatg 
      961 tatcaaccta gtgctgtggt attacagtgt ggtgcagact cattatctgg tgatagactg 
     1021 ggttgtttca atctaacagt caaaggtcat gctaaatgtg tagaagttgt aaaaactttt 
     1081 aacttaccat tactgatgct tggaggaggt ggctacacaa tccgtaatgt tgctcgatgt 
     1141 tggacatatg agactgcagt tgcccttgat tgtgagattc ccaatgagtt gccatataat 
     1201 gattactttg agtattttgg accagacttc aaactgcata ttagtccttc aaacatgaca 
     1261 aaccagaaca ctccagaata tatggaaaag ataaaacagc gtttgtttga aaatttgcgc 
     1321 atgttacctc atgcacctgg tgtccagatg caagctattc cagaagatgc tgttcatgaa 
     1381 gacagtggag atgaagatgg agaagatcca gacaagagaa tttctattcg agcatcagac 
     1441 aagcggatag cttgtgatga agaattctca gattctgagg atgaaggaga aggaggtcga 
     1501 agaaatgtgg ctgatcataa gaaaggagca aagaaagcta gaattgaaga agataagaaa 
     1561 gaaacagagg acaaaaaaac agacgttaag gaagaagata aatccaagga caacagtggt 
     1621 gaaaaaacag ataccaaagg aaccaaatca gaacagctca gcaacccctg aatttgacag 
     1681 tctcaccaat ttcagaaaat cattaaaaag aaaatattga aaggaaaatg ttttcttttt 
     1741 gaagacttct ggcttcattt tatactactt tggcatggac tgtatttatt ttcaaatggg 
     1801 actttttcgt ttttgttttt ctgggcaagt tttattgtga gattttctaa ttatgaagca 
     1861 aaatttcttt tctccaccat gctttatgtg atagtattta aaattgatgt gagttattat 
     1921 gtcaaaaaaa ctgatctatt aaagaagtaa ttggcctttc tgagctgaaa aaaaaaaaaa 
     1981 aaaag 
 
 
Figure 3.3 HDAC2 mRNA and location of siRNA sequences. Three siRNA 
sequences against HDAC2 (2A, 2B, and 2C) were purchased from Invitrogen and their 





3.5 Colony Formation Assay 
Between 24 to 48 hours after transfection or drug treatment, cells were 
harvested by trypsinization and counted using the hemocytometer. Depending on the 
cell type, 1000 to 5000 cells were plated into each well in a 6 well plate, in triplicate 
wells. The plates were returned to the incubator. 
At the end of 7 to 14 days, depending on the cell type, the wells were washed 
in 1X PBS and the colonies stained with crystal violet solution. The plates were then 
scanned and the images were analysed using the ImageJ (NIH) software to measure 
the number of colonies formed in each well. 
 
3.6 WST-1 Cell Proliferation Assay 
To measure cell proliferation, the colorimetric assay was performed using 
WST-1 reagent (Roche). 
3.6.1 Cell plating 
Twelve hours post-transfection, cells were trypsinized, counted by 
hemocytometer, and replated at 500 cells/well in a 96well plate. This was done for 6 
plates with 5 replicate wells for each sample on each plate. These plates were placed 
in the humidified 37C incubator with 5% CO2 until they are ready to be assayed.  
3.6.2 WST-1 Assay 
Thirty-six hours post-transfection (24h after replating), 10l of WST reagent 
was added to each well containing 100l of media. The plate was returned to 
humidified 37C incubator with 5% CO2 for 4 hours before the absorbance was read 
at 460nm using a spectrophotometer. A “blank” well with only the media and WST 
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reagent but without cells was used as negative control. Subsequently, at 24 hours 
interval, one plate will be assayed until all the 6 plates were read after 6 days.  
 
3.7 Cell cycle analysis 
3.7.1 Collection of cells for fixation 
Cells were washed in 1X PBS, trpysinized, and collected. Both the live 
adherent and dead floating cells were collected and pelleted at 2500 RPM for 5 min at 
4C. They were washed 1X PBS, fixed in cold 70% ethanol and stored in -20C for 
overnight. 
Staining with propidium iodide: 
The fixed cells were centrifuged at 2500 RPM for 5 min at 4C and washed once in 
1X PBS. They were then resuspended in 500l propidium iodide (PI) staining 
solution (0.1% triton-X, 0.2mg/ml RNaseA, 0.02mg/ml propidium iodide, in 1XPBS) 
and incubated for 15 min at 37C in the dark. 
3.7.2 Flow cytometry 
The PI-stained cells were filtered through a 40m filter before being run 
through a Beckman Coulter Epics Altra at the Flow Cytometry Unit at National 
University Medical Institute. Ten thousand cells were analysed for each sample to 
generate a cell cycle profile. Analysis was done using the WinMDI software. 
 
3.8 Cloning of pcDNA-HDAC1 and pcDNA-HDAC2 plasmids 
3.8.1 PCR to amplify DNA and DNA fragment purification by gel extraction 
The full length HDAC1 and HDAC2 coding sequences were amplified from 
the cDNA of HCT116 cells using primers engineered with the BamH1 and Xho1 
restriction sites at the 5’ and 3’ ends respectively. The PCR products were run on a 
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1.2% agarose gel in 0.5X TBE, at 100V for 1hour. The DNA fragments were excised 
under brief UV light and gel extraction was done using the QIAquick Gel Extraction 
kit (Qiagen) according to the manufacturer’s instructions. The purified PCR products 
of HDAC1 and HDAC2, as well as the pcDNA3.1 vector (Invitrogen), were cut using 
BamH1 and Xho1 enzymes from Promega for 3 hours at 37C before the enzymes 
were inactivated at 65C for 15 min. The digested fragments of HDAC1, HDAC2 and 
pcDNA3.1 vector were run on a 1.2% agarose gel and gel extraction was done using a 
kit (Qiagen) according to the manufacturer’s instructions. 
3.8.2 Ligation 
The purified HDAC1 and HDAC2 fragments were ligated into the pcDNA3.1 
vector using T4 Ligase (Promega) and the 2X Rapid Ligase Buffer (Promega) in 4C 
for 16 hours. 
3.8.3 Transformation 
Ten percent of each ligation mixture was incubated with 50l of freshly 
thawed XL1Blue competent cells on ice for 30 min, heat-shocked at 42C for 45 sec 
and immediately cooled in ice for 2 min. The transformed cells were then cultured in 
250l of SOC medium in an orbital shaker at 37C for 1 hour. One hundred l of the 
bacteria culture were then plated onto LB agar plates containing ampicillin 
(100g/ml), IPTG (100nM) and X-gal (1.75mg) and grown for 16 hours in 37C 
incubator. The next day, white colonies were picked from each plate and cultured in 
3ml LB media with ampicillin (100g/ml) in an orbital shaker at 37C for 16 hours.  
3.8.4 Plasmid miniprep 
Bacterial pellets were obtained for each sample by centrifuging 2ml of the 
culture in a tube. The remaining 1ml culture was stored in 4C for future inoculation 
into larger culture volume if the sample was verified to be positive.  
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Plasmid DNA was extracted from the bacterial culture using the QIAprep 
Miniprep kit (Qiagen). Briefly, the bacterial pellets were resuspended in a pre-lysis 
buffer and a lysis solution was then added until a clear and viscous lysate was 
obtained. With the addition of a neutralizing buffer, the bacterial membrane, proteins 
and chromosomal DNA would be precipitated and spun down at 14,000x g for 10 
min. The supernatant, which contained the plasmid DNA, was allowed to bind to the 
spin column provided in the kit and washed. This plasmid DNA was eluted with 30l 
of buffer.  
3.8.5 Verification of positive clones 
The plasmid DNA from each sample was digested with BamH1 and Xho1 
(Promega) for 3 hours at 37C. The digested reaction was run on 1.2% agarose gel 
and the sizes of the bands were verified to match that of the DNA insert and pcDNA 
vector. 
3.8.6 Plasmid midiprep 
The 1ml bacteria cultures from the positive clones were inoculated into 50ml 
of LB media containing ampicillin (100g/ml) and incubated in an orbital shaker at 
37C for 16 hours. Plasmid DNA was extracted from the bacteria culture using the 
HiSpeed Plasmid Midi Purification kit (Qiagen). The 50ml bacteria culture was 
centrifuged and the pellet was resuspended in buffer P1 (with added RNase A), 
followed by the addition of buffer P2 for lysis and P3 for neutralization and 
precipitation of proteins and chromosomal DNA. The precipitates were filtered and 
the lysate were allowed to bind to the HiSpeed Tip, washed, and eluted with buffer 
QF. The plasmid DNA was then precipitated using isopropanol and allowed to bind to 
the QIA precipitator. Elution was done with TE buffer and the concentration of the 
DNA was measured using UV spectrophotometry.  
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3.8.7 Sequencing reaction 
The plasmids were sequenced to ensure that there is no mutation in the DNA. 
The Big-Dye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied 
Biosystems) was used to perform the sequencing reaction, which was read using the 
automated ABI Prism 377 sequencer (Amersham) at the National University of 
Singapore Medical Institutes’ sequencing facility. 
The sequencing reaction consisted of 300ng of DNA, 6l of Terminator Ready 
Reaction Mix containing DNA polymerase, buffer, and dideoxynucleotide (ddATP, 
ddVTP, ddGTP and ddTTP), 2l of 5X sequencing buffer, and 3.2pmol of sequencing 
primer. The final volume was made up to 20l using deionized water. The mixture 
was subjected to 25 cycles of thermal sequencing on a GeneAmp 2720 system (PE 
Applied Biosystems): 95C for 10 sec, 50C for 5 sec, and 60C for 4 min. The 
extension products were purified by ethanol precipitation and the pellet was air-dried 
before being reconstituted in sequencing loading buffer and sequenced using the ABI 
Prism 377 sequencer. 
 
3.9 Site-directed mutagenesis 
To generate enzyme-dead mutants of HDAC1 and HDAC2 plasmids, 
QuikChangeII site-directed mutagenesis kit (Stratagene) was used to mutate 2 
nucleotides within the catalytic domain of the enzyme based on Hassig et al. (Hassig 
et al., 1998). This mutation changed the amino acid number 141 from a histidine to an 
alanine in the HDAC1 protein, which was verified by Hassig et al. to maintain native 
folding but confer no HDAC enzyme activity. Because this catalytic domain is 
identical between HDAC1 and HDAC2, we also mutated the same 2 nucleotides in 
order to change amino acid number 142 from histidine to alanine to generate a 
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HDAC2 enzyme dead mutant.  Primers were designed using the program provided on 
the Stratagene website http://www.stratagene.com/sdmdesigner/default.aspx 
Table 3.2 Primer sequences used for generating HDAC1 and HDAC2 mutants. 
Mutant Primer name Primer sequence (5’to 3’) 
HDAC1 H141A ctgggggcctgcacgctgcaaagaagtccg 
 H141A_antisense cggacttctttgcagcgtgcaggcccccag 
HDAC2 H142A gggctggaggattacatgctgctaagaaatacgaagc 
 H142A_antisense gcttcgtatttcttagcagcatgtaatcctccagccc 
 
These primers were synthesized (Sigma-Proligo) and HPLC purified. The mutant 
strand synthesis reaction was set up as below: 
5l of 10X reaction buffer 
Xl (50ng) of dsDNA template (either pcDNA-HDAC1 or pcDNA-HDAC2) 
Xl (125ng) of primer#1 (H141A or H142A) 
Xl (125ng) of primer#2 (H141A_antisense or H142A_antisense) 
1l of dNTP mix 
ddwater to a final volume of 50l 
then add 1l PfuUltra HF DNA polymerase (2.5U/l) 
Table 3.3 Cycling parameters used for site-directed mutagenesis. 
Segment Cycles Temperature Time 
1 1 95C 30 sec 
2 16 95C 30 sec 
55C 1 min 
68C 5 min 
 
At the end of the temperature cycling, the reactions were placed on ice for 2 min. 
Then 1l of the Dpn1 restriction enzyme was added to each reaction and incubated at 
37C for 1 hour to digest the parental nonmutated supercoiled dsDNA. Subsequently, 
the reactions were used in transformation of the XL1-Blue supercompetent cells 
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provided in the kit and positive clones were picked for plasmid extraction using 
Miniprep and Midiprep as described previously. Verification was performed by 
sequencing of the plasmids to ensure that the mutations were achieved. 
 
3.10 Immunoprecipitation 
3.10.1 Cell lysis 
Cells were washed twice in cold 1X PBS before being lysed by cold RIPA 
Buffer (1% NP40, 1% Sodium Deoxycholate, 0.1% SDS, 0.15M sodium chloride, 
50mM Tris pH8) with freshly added cocktail protease inhibitor (Roche). After 
incubating for 15 min on a rotator at 4C, the lysed cells were scraped and transferred 
to a tube for further rotation at 4C for 10 min. The samples were centrifuged at 
12,000 RPM at 4C for 15 min and the supernatant was collected as the cell lysate. 
Quantification of protein was performed as described in the previous section. Equal 
amount of protein (1-5mg) was taken from each lysate sample and made up to the 
same volume for immunoprecipitation. 
3.10.2 Binding with antibodies and beads 
One g of primary antibody was added to each sample. As a negative control, 
either mouse IgG or rabbit IgG was used depending on the source of the antibody 
used. The samples were incubated for 2 hours on a rotator at 4C. Protein G beads 
(Amersham) was washed and equilibrated with RIPA buffer and added to each 
sample, to be incubated for 2 hours on a rotator at 4C. 
3.10.3 Elution 
The beads were washed in cold 1X PBS for 5 min for 3 times. Loading buffer 
was diluted to be 2X and 35l was added to each sample, which was placed in a heat 
block at 95C for 4 min to elute the immunoprecipitates. The immunoprecipitates 
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were carefully loaded into the wells of a polyacrylamide gel. The subsequent steps 
were described in the previous section on Western Blot. 
 
3.11 HDAC Activity Assay 
3.11.1 Extraction of nuclear protein 
Cells were washed in 1X PBS and collected by trypsinization and pelleted at 
1000 RPM for 5 min at 4C. The cell pellet was lysed in a cold lysis buffer (0.65M 
sucrose, 20mM Tris pH8.0, 10mM magnesium chloride, 2% Triton-X) on ice for 15 
min. The samples were centrifuged at 2000 RPM for 5 min at 4C and the supernatant 
containing the cytoplasmic protein was removed. The nuclear pellet was resuspended 
and lysed in ice for 20 min in a NT Buffer (50mM Tris pH7.4, 100mM sodium 
chloride, 5mM magnesium chloride, 5mM calcium chloride, 1% NP40, 1% Triton-X, 
10units of DNaseI) with freshly added cocktail protease inhibitor (Roche). The 
samples were centrifuged at 13,000 RPM for 15 min at 4C and the supernatant from 
each was collected as the nuclear lysate. Protein quantification was done as described 
in the previous section. 
3.11.2 Fluorometric HDAC Activity Assay 
The global histone deacetylase activity of each sample was measured using the 
HDAC Assay Kit according to manufacturer’s instructions (Upstate). Briefly, 5g of 
the nuclear protein was incubated with the substrate in a half-volume plate provided 
in the kit at 37C for 30 min. An activator solution with the HDAC inhibitor 
Trichostatin (TSA) was added to stop the enzymatic reaction and to give a 
fluorometric signal, to be read on a fluorescence plate reader with an excitation of 
360nm and emission of 460nm. Each sample was done in duplicates and the average 
counts per second (CPS) was taken. 
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To measure the HDAC activity of HDAC1 and HDAC2 in a cell lysate sample 
specifically, immunoprecipition was performed using the HDAC1 and HDAC2 
antibodies respectively, as described in the previous section. Instead of eluting the 
immunoprecipitates from the beads using the loading buffer, the beads were washed 
in the HDAC Assay Buffer provided in the kit and incubated with the substrate at 
37C for 30 min. The samples were centrifuged at 8000x g for 30 sec to pellet the 
beads and the supernatant was transferred to the plate to be incubated with the 
activator solution and read using the fluorescence plate reader. 
 
3.12 RNA isolation 
Total RNA was extracted from cells using the Qiagen RNeasy Mini Kit 
according to the manufacturer’s instructions (Qiagen). Briefly, cells were harvested 
by trypsinization and washed in 1X PBS. They were then lysed by 350l RLT buffer 
containing 10l beta-mercaptoethanol and homogenized using needle and syringe. 
Equal volume of 70% ethanol was added and each sample was applied to the RNeasy 
minispin column for centrifugation at 10,000x g for 30 sec. This was followed by 2 
washing steps with 500l of RPE buffer and a drying step to remove all traces of the 
ethanol in the buffer by centrifugation at 10,000x g for 2 min. Finally the RNA was 
eluted with 35l of RNase-free water. Quantification of RNA was done at 260nm. 
 
3.13 Microarray 
HEB3B cells were transfected with siRNA against HDAC1 or/and HDAC2 as 
described in the previous section. Seventy-two hours after transfection, cells were 
harvested for protein and RNA extraction. After verifying by Western blot that the 
efficiency of knockdown was satisfactory, the RNA was quantified. In addition, 
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another set of HEP3B cells were treated with either 2000nM PXD101 (HDAC 
inhibitor) or vehicle control for 24hours and RNA extraction was done. Gene 
expression profiles of samples after each treatment were examined using the Illumina 
HumanRef-8 v3 beadchip which has 24,526 probes in each array. Analysis was done 
using Genespring version 2. Gene ontogeny pie chart was generated based on the 
Gene Ontogeny (GO) classification by molecular function, biological process and 
cellular component using the Protein ANalysis THrough Evolutionary Relationships 
(PANTHER) classification system (Thomas et al., 2003). 
 
3.14 Real-time RT-PCR 
3.14.1 cDNA synthesis 
One g of RNA was used for cDNA synthesis. The reaction was set up as 
follows: 5l of RNA, 1.25l of Oligo dT, 1.25l dNTP, 7.5l DEPC water. This was 
incubated for 5min at 65oC before adding the following: 5l first strand buffer 
(Invitrogen), 2.5l 0.1M DTT, 1.25l DEPC water, 1.25l ImpromII Reverse 
Transcriptase (Promega). The reaction was incubated at 42oC for 60 min. For 
subsequent PCR, 1 out of 25l total volume was used. 
3.14.2 Quantitative PCR 
Using the Roche LightCycler SYBR Green DNA amplification kit (Roche 
Diagnostics, Mannheim, Germany), quantitative PCR was performed according to 
manufacturer’s specification on the Roche LightCycler 480 machine. Each reaction 
sample was set up in duplicates in a special 96 well plate (Roche) with 10l of the 2X 
reaction mix, 1l of cDNA, 1µl of forward primer (10µM) and 1µM of reverse primer 




Table 3.4 List of primers used in RT-PCR. 
Gene Forward Primer (5'-3') Reverse Primer (5'-3') 
MAGEC2 AGGCGCGAATCAAGTTAG CTCCTCTGCTGTGCTGAC 
NMES1 AGGAACTCATTCCCTTGGTG TCCACAGTTTCCCAAGGTTC 
NOTCH3 AAGGACGTGGCCTCTGGT TCAGGCTCTCACCCTTGG 























HDAC1 AACTGGGGACCTACGG ACTTGGCGTGTCCTT 
HDAC2 GTTGCTCGATGTTGGAC CCAGGTGCATGAGGTA 
 
The amplification involved an initial denaturation step of 2 min, followed by 
40 cycles of denaturation step at 95C for 0 sec, annealing at 60C for 10 sec and 
extension at 72C for 10 sec. At the end of each cycle, the SYBR Green fluorescence 
emitted was measured. The crossing point (CP) for each reaction was determined by 
the software based on the fluorescence signal. The mRNA expression for each sample 
was calculated according to the Roche Applied Science Technical Note No. LC 













CHAPTER 4 RESULTS 
 
4.1 HDAC1 and HDAC2 expression in human liver cancer  
4.1.1 HDAC1 and 2 expression was increased in human hepatocellular 
carcinoma protein extracts 
Protein extracts from 28 pairs of hepatocellular carcinoma and their matched 
adjacent non-tumor tissue were obtained from the National University Hospital Tissue 
Repository with Institutional Review Board (IRB) approval. The protein expression of 
HDAC1 and HDAC2 were examined by Western blot as shown in Figure 4.1, with 
GAPDH as the loading control. The bands of HDAC1 and HDAC2 on the blots were 
then quantified by densitometry and normalized against that of GAPDH. Figure 4.2 
shows the fold increase in HDAC1 and HDAC2 protein expression in the tumor 
versus the matched non-tumor tissues. Of the 28 pairs of samples, 8 were not 
quantified because the band on the blot was not well-defined enough to be imaged 
accurately for densitometry. Altogether, 68.4% (13 out of 19 pairs) showed an 
upregulation of HDAC1 in the tumor compared to the matched non-tumor tissue, 
while 85.2% (23 out of 27) showed upregulation of HDAC2 in the tumor compared to 
the matched non-tumor tissue, and 63.2% (12 out of 19 pairs) showed upregulation of 
both HDAC1 and 2. Therefore, majority of the matched hepatocellular carcinoma 
tissues have upregulated protein expression HDAC1 and 2. 
4.1.2 HDAC1 and 2 expression was increased in human hepatocellular 
carcinoma tissues by tissue microarray analysis 
Tissue microarray from 179 pairs of hepatocellular carcinoma and their 
matched adjacent non-tumor tissue were obtained from the Department of Pathology 





Figure 4.1 Protein expression of HDAC1 and HDAC2 are upregulated 
in liver tumor tissues compared to the matched adjacent normal 
tissues. Fifteen µg of protein from each sample was loaded and 
immunoblotted using anti-HDAC1 and anti-HDAC2 antibodies. GAPDH 
was used as a loading control. T represents the tumor tissue while N is the 




Figure 4.2 Densitometry to quantitate the fold increase in HDAC1 
and HDAC2. The protein expression of HDAC1 (A) and HDAC2 (B) 




morphologically representative area on a bigger tissue block, as annotated by the 
pathologist. Immunohistochemistry was performed to examine the expression of 
HDAC1 and HDAC2 on these samples separately. Scoring was done based on the 
staining intensity of the hepatocytes’ nuclei, with a score ranging from 0 to 3 (Figure 
4.3). The number of samples with the various scores was tabulated in Table 4.1A. To 
find out if a matched sample pair has an upregulation of HDAC1 and HDAC2, the 
score for the non-tumor was subtracted from that of the tumor for each matched pair. 
Therefore, each matched pair would have a HDAC1 and HDAC2 index (T-N) ranging 
from -3 to 3. A negative index would indicate a downregulation of the protein in the 
tumor compared to the matched non-tumor, while a positive index would indicate an 
upregulation, and an index of 0 would indicate no change. Table 4.1B shows the 
number of samples with the various indices for HDAC1 and HDAC2. Majority of 
them have either no change or upregulation in HDAC1 and HDAC2. Of the 179 pairs, 
58.1% (104 out of 179) has an upregulation of HDAC1, while 66.5% (119 out of 179) 
has an upregulation of HDAC2 (Table 4.1C). There was 46.4% (83 out of 179) with 
an upregulation in both HDAC1 and HDAC2; 14.5% (26 out of 179) of them with no 
change in both, but only 1.7% (3 out of 179) with a downregulation in both. 
4.1.3 Correlation of HDAC1 and 2 expressions in hepatocellular carcinoma 
tissues with clinicopathological parameters 
Clinicopathological factors were compared with the HDAC1 and HDAC2 
expression in the tissue samples (Table 4.2). Among the parameters that were 
analyzed, upregulation in HDAC1 expression in the matched tumor sample was 
correlated with HBV status of the patient (p-value=0.039). Interestingly, patients who 






Figure 4.3 Immunohistochemical analysis of hepatocellular 
carcinoma tissue microarray. Representative examples of scoring 
performed on HDAC1 and HDAC2 staining.  A tissue section with 
negative staining was given a score 0 while score 1 to 3 indicated 
increasing intensity of nuclear staining of the hepatocytes. Magnification 





Table 4.1 Summary of HDAC1 and 2 grading scores for HCC Tissue 
Microarray samples. A, The number of samples with a score of 0 to 3 for 
HDAC 1 and 2 in the tumor (T) and non-tumor (N) samples are shown. B, 
To obtain an index to whether the HDAC expression is upregulated, the 
score of the non-tumor sample was subtracted from that of the matched 
tumor sample. The table shows the number of samples with an HDAC1 or 2 
index ranging from -3 to +3. A negative index indicates a downregulation 
whereas a positive index indicates an upregulated of HDAC1 or 2 in the 
matched tumor and non-tumor sample. An index of zero indicates no change 
in HDAC1 or 2 expression between the matched tumor and non-tumor 
sample. C, This crosstable shows the number of samples with either 







downregulated HDAC1 expression in their tumor with p-value of 0.021 and 0.020 
respectively. Chi-square test was used in the above analysis. 
4.1.4 Correlation of HDAC1 and 2 expressions with patient survival rates 
Kaplan-Meier analysis was used to study how the HDAC1 and HDAC2 
expression affects survival rates of patients. Using the HDAC1 and HDAC2 indices, 
which are measures of the respective HDAC expressions in the tumor compared to the 
matched non-tumor sample (T-N), the cumulative survival ratio of the total population 
of samples was plotted over 6 years (Figure 4.4). There is a general trend that patients 
with higher HDAC1 index, indicating a higher upregulation of HDAC1 in the tumor 
compared to the matched non-tumor sample, have shorter survival time (Figure 4.4A). 
However, such trend was not observed when HDAC2 index was used for the same 
analysis (Figure 4.4B). To simplify the analysis, the matched samples were further 
categorized into low expression (T-N index equals or less than 1) or high expression 
(T-N index more than 1) for HDAC1 and HDAC2 separately. The cumulative 
survival ratio of the total population of samples was plotted over 6 years (Figure 4.5). 
Patients with higher HDAC1 index have a significantly poorer prognosis compared to 
those with a lower index (p=0.037). Those with a higher HDAC2 index showed 
slightly poorer prognosis from the 2nd year onwards but it was overall not statistically 
significant (p=0.511). To control for other parameters which may also affect survival 
of liver cancer patients, a Cox Regression (Table 4.3) was done and higher HDAC1 
expression remained as a significant prognosis factor for poorer survival (p=0.015). 
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Figure 4.4  Kaplan-Meier curve to compare survival rate of patients with 
different HDAC indices. A, Patients with a higher HDAC1 index generally 
has a lower survival rate than those with a lower HDAC1 index (p=0.149). B, 







Kaplan-Meier survival analysis based on HDAC1 expression 
Kaplan-Meier survival analysis based on HDAC2 expression 
P=0.511 
P=0.037 
Figure 4.5  Kaplan-Meier curve to compare survival rate of patients 
with a HDAC index of less than or equal to 1, against those with an 
index of more than 1. A, Patients with a higher HDAC1 index has a lower 
survival rate than those with a lower HDAC1 index (p=0.037). B, There is 
no statistical significance in the survival rates of patient with higher or 







4.1.5 Expressions of HDAC1 and 2 in various colon and liver cancer cell lines 
The protein expression of HDAC1 and HDAC2 was examined in various 
colon (HT29, RKO, and HCT116) and liver (HEP3B, HEPG2, PLC5) cancer cell 
lines. As shown in Figure 4.6, both HDAC1 and HDAC2 were expressed in all the 
cell lines tested.  
 
4.2 Verification of efficiency and specificity of siRNA against HDAC1 and 2 
A knockdown strategy was used to study the functions of HDAC1 and 
HDAC2 in cells. Because of the high homology between HDAC1 and HDAC2, it is 
important to ensure that the siRNA designed to silence the expression of HDAC1 and 










Figure 4.6 Comparison of HDAC1 and 2 protein expression among the 
various colon and liver cancer cell lines.  Protein was extracted from the 
human colorectal cancer cell lines HT29, RKO and HCT116 as well as the 
liver cancer cell lines HEP3B, HEPG2, and PLC5. Western blot was 
performed using anti-HDAC1 and anti-HDAC2 antibodies. GAPDH was 
used as loading control. 
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After transfecting HEP3B cells with the individual siRNA sequences 
individually, RNA was extracted and the mRNA expression of HDAC1 and HDAC2 
was quantified using real-time RT-PCR. Results showed that the siRNA sequences 
against HDAC1 can reduce HDAC1 expression without reducing that of HDAC2, and 
vice versa (Figure 4.7). There was at least 8-fold decrease in gene expression when 
the individual siRNA were used for the specific HDAC. In other words, the siRNAs 
were both specific and efficient in knocking down HDAC1 and HDAC2. Similar level 
of knockdown was achieved when the sequenced were mixed to knockdown HDAC1 
and 2 together. Western blot was used to verify that the knockdown specificity and 
efficiency was demonstrated at the protein level as well. The siRNA was specific and 
efficient when used separately (Figure 4.8A) or when the 3 sequences were pooled to 
be used together (Figure 4.8B). Subsequently, the siRNA were pooled together to 
knockdown HDAC1 or HDAC2 or both. 
It is interesting to note that while the siRNA against HDAC1 and HDAC2 was 
specific in knocking down the respective HDACs, the knockdown of one seemed to 
increase the protein expression of the other (Figure 4.8). This phenomenon was 
consistent in both the HCT116 and HEP3B cells.  
 
4.3 Effects of HDAC1 and 2 knockdown on cancer cells survival 
4.3.1 Reduction of colony formation after knockdown of both HDAC1 and 2 in 
different cell lines 
The expression of HDAC1 and HDAC2 were knocked down individually or 
together in 3 liver cancer cell lines and 1 colorectal cancer cell line: HEP3B, HEPG2, 
PLC5, and HCT116. After transfection, the cells were allowed to recover overnight 




Figure 4.7 Quantitative real time RT-PCR to show efficiency and 
specificity of HDAC1 and HDAC2 knock-down. HEP3B cells were 
transfected with either HDAC1 or HDAC2 specific siRNA for 72 hours. 
Cells were harvested and RNA extracted and used for quantitative real time 
RT-PCR, done in replicates. The sequences specific for HDAC1 (1A and 
1B) resulted in reduced RNA expression of HDAC1 compare to the non-
silencing control (Scr) but not HDAC2, and the sequences specific for 
HDAC2 (2A, 2B, and 2C) resulted in reduced RNA expression of HDAC2 
compare to the non-silencing control (Scr) but not HDAC1. Data is from 


















Figure 4.8 Western blot to show specificity and efficiency of HDAC1 and 
HDAC2 knockdown. A, HCT116 cells were transfected with either HDAC1 
or HDAC2 specific siRNA (3 sequences for each HDAC) for 72 hours. Cells 
were harvested and total protein extracted. Western blot was done using 
antibody for either HDAC1 or HDAC2. The 3 sequences specific for 
HDAC1 (1A, 1B, and 1C) resulted in reduced protein expression of HDAC1 
compare to the non-silencing control (Scr) but not HDAC2, and the 3 
sequences specific for HDAC2 (2A, 2B, and 2C) resulted in reduced protein 
expression of HDAC2 compare to the non-silencing control (Scr) but not 
HDAC1. There was a slight upregulation of HDAC1 when HDAC2 was 
silenced, and vice versa. GAPDH was used as loading control. B, HEP3B 
cells were transfected with a mixture of 3 siRNA sequences against HDAC1 
(H1), or HDAC2 (H2), or 6 siRNA sequences against both HDAC1 and 
HDAC2 (H1+2), or the non-silencing control (Scr) for 72 hours before being 
harvested for protein for Western blot using HDAC1 and HDAC2 specific 
antibodies. There was a slight upregulation of HDAC1 when HDAC2 was 
silenced, and vice versa. GAPDH was used as loading control. 
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4.9 shows the western blot to verify the knockdown of HDAC1 and/or HDAC2 
proteins. Figure 4.10 shows the representative images of colonies formed after 
treatment with HDAC1 or/and HDAC2 siRNA, the non-silencing siRNA control (Scr) 
or the untransfected control (Ctrl). The number of colonies in each well was counted 
by ImageJ software and the quantified data is shown in Figure 4.11. In all the 4 cell 
lines tested, the number of colonies formed was reduced, to varying degrees, when 
both HDAC1 and 2 were knocked down together. However, in all the cell lines tested, 
this effect was not observed when HDAC1 and 2 were silenced individually.  
4.3.2 Reduction in cell proliferation over 6 days after knockdown of both 
HDAC1 and 2 
To observe the growth curve of cells after knocking down HDAC1 and 
HDAC2, HEP3B cells were treated with HDAC1 or/and HDAC2 siRNA, the non-
silencing siRNA control (Scr) or the untransfected control (Ctrl) and replated in 96-
well dishes. WST-1 assay was performed to assess cell number as a surroagate 
measure of proliferation of these cells over 6 days. Figure 4.12 shows that the growth 
of the HEP3B cells with both HDAC1 and 2 silenced stopped growing after 72 hours, 
and the cell number started to decrease from that point until 120 hours post-
transfection. On the other hand, individually knocking down HDAC1 or HDAC2 did 
not have significant effect on the cell proliferation over time.  
4.3.3 Cell cycle profile analysis showed increase in apoptosis in cells after 
knockdown of HDAC1 and 2 
To account for the reduced colony formation and proliferation of the cells after 
knocking down HDAC1 and 2 expressions, we used flow cytometry to examine their 
cell cycle profiles (Figure 4.13). Gating was done to quantify the percentage of the 























Figure 4.9 Knockdown of protein expression of HDAC1 or/and 
HDAC2 in HEP3B, HEPG2, PLC5, and HCT116 cells. Cells were 
transfected with HDAC1 siRNA (H1), or HDAC2 siRNA (H2), or both 
(H1+2), or non-silencing control siRNA (Scr). After 72 hours, cells were 
harvested for protein and Western blot using HDAC1 and HDAC2 specific 




Figure 4.10 Effect of knocking down HDAC1 or/and HDAC2 in 
HEP3B, HEPG2, PLC5, and HCT116 cells. Cells were transfected with 
HDAC1 siRNA (H1), or HDAC2 siRNA (H2), or both (H1+2), or non-
silencing control siRNA (Scr) or untransfected (Ctrl). They were allowed to 
recover overnight before being counted and replated at low density. After 
10 days, the colonies were stained with crystal violet and the wells were 
imaged. The knockdown of both HDAC1 and 2 together is required to 







Figure  4.11 Quantification of colony formation in HEP3B. (A), HEPG2 (B), 
PLC5 (C), and HCT116 (D) cells after knocking down HDAC1 or/and HDAC2. 
The average number of colonies in each of the triplicate wells were plotted 
against the treatment. Error bars showed standard deviations. The knockdown of 





Figure 4.12 WST-1 assay showed that knocking down HDAC1 and 2 
can reduce cell growth over time. HEP3B cells were transfected with 
HDAC1 siRNA (H1), or HDAC2 siRNA (H2), or both (H1+2), or non-
silencing control siRNA (Scr) or untransfected (Ctrl). They were allowed to 
recover overnight before being counted and replated in 5 replicates into six 
96-well dishes. Each plate was taken out for WST-1 assay at the various 
time points. Error bars showed standard deviations. 
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Figure 4.13 Cell cycle analysis of HEP3B cells. Histograms to show the 
cell cycle profiles of HEP3B cells at 72 hours and 96 hours after siRNA 
treatment to knockdown HDAC1 or/and HDAC2. HEP3B cells were 
transfected with HDAC1 siRNA (H1), or HDAC2 siRNA (H2), or both 
(H1+2), or non-silencing control siRNA (Scr) or untransfected (Ctrl). The 






Figure 4.14 Quantification of the percentages of cells in each phase of 
the cell cycle at 72 hours (A) and 96 hours (B) after siRNA treatment to 
knockdown HDAC1 or/and HDAC2 in HEP3B cells. The knockdown of 
both HDAC1 and 2 together increased the percentage of cells in the subG1 
and reduced the percentage of cells in the G1 phase of the cell cycle. Data 
is representative of 3 independent experiments. 
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The cell cycle profiles of HEP3B cells transfected with HDAC1 or HDAC2 siRNA 
individually, or the non-silencing siRNA (Scr), or the untransfected control, remained 
unchanged after 72 and 96 hours. For cells that had both HDAC1 and HDAC2 
knocked down, the percentage of their subG1 fraction increased while that of the G1 
decreased. This observation was more prominent at 96 hours than 72 hours post-
transfection. A closer examination of the subG1 fractions of the cell population, 
which represents the apoptotic cells, showed that the percentage of cells increased 
from 8 % at 72 hour to 22.5% at 96 hours post-transfection, whereas it was only about 
2% in the control (Figure 4.15). This is consistent with the time points when a drop in 
the growth curve was seen as described in the previous section. 
4.3.4 Changes in expression of apoptotic proteins after knockdown of HDAC1 
and 2 
Western blot was done to check the efficiency of knockdown as well as the 
expression of various proteins involved in apoptosis. Figure 4.16 shows that the 
knockdown was sustained throughout the period from 72 hours to 120 hours post-
transfection. There was cleavage of caspase 3 from 96 hours to 120 hours post-
transfection. This caspase 3 was active as indicated by the cleavage of its substrate 
PARP. Another apoptotic protein BCL2 remained unchanged. 
4.4 Mechanisms for reduced cell survival after knockdown of HDAC1 and 2 
4.4.1 Synergistic reduction in global HDAC activity after knockdown of 
HDAC1 and 2 
We used a HDAC activity assay to measure the global HDAC activity in the 
cell after knocking down HDAC1 or/and HDAC2. Figure 4.17A shows that while 






Figure 4.15 Apoptosis occurs in Hep3B cells at 72 h and 96 h after 
knocking down both HDAC1 and HDAC2. From the cell cycle analysis, 
the percentage of cells in the subG1 phase was plotted for the respective 
siRNA treatments in HEP3B cells, at 72 and 96 hours post-transfection. 





Figure 4.16 Increase in apoptotic proteins after HDAC1 and 2 
knockdown. Expression of apoptotic proteins in HEP3B at various 
timepoints after being transfected with siRNA against HDAC1 (H1) or 
HDAC2 (H2) or both (1+2) or non-silencing control (Scr) or untransfected 
control (ctrl). There was cleavage of caspase 3 as well as PARP. However, 







Figure 4.17 HDAC activity in HEP3B cells is synergistically reduced by 
HDAC1 and 2 knockdown. A, HEP3B cells were transfected with siRNA 
against HDAC1 (H1) or HDAC2 (H2) or both (1+2) or non-silencing 
control (Scr) or untransfected control (ctrl) for 48 hours before the nuclear 
extract was used to test for HDAC activity. B, Western blot shows effective 
and specific knockdown of HDAC1 or/and HDAC2. Acetylated histone H3 
(Ac-H3) was upregulated after knocking down both HDAC1 and 2. Lamin 
B was used as loading control for the nuclear extract. 
Figure 4.17 HDAC activity in HEP3B cells is synergistically reduced by 
HDAC1 and 2 knockdown. A, HEP3B cells were transfected with siRNA 
against HDAC1 (H1) or HDAC2 (H2) or both (1+2) or non-silencing 
control (Scr) or untransfected control (ctrl) for 48 hours before the nuclear 
extract was used to test for HDAC activity. Data is obtained from duplicates 
and is representative of 3 experiments. B, Western blot shows effective and 
specific knockdown of HDAC1 or/and HDAC2. Acetylated histone H3 
(Ac-H3) was upregulated after knocking down both HDAC1 and 2. Lamin 
B was used as loading control for the nuclear extract. 
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silencing HDAC1 can partially reduce HDAC activity. When both HDAC1 and 2 
were knocked down together, there was synergistic reduction in HDAC activity in the 
cells. This correlates with the colony formation assay results. Figure 4.17B shows that 
the nuclear extract used in the HDAC assay was verified to show effective HDAC1 
or/and HDAC2 knockdown, as well as an upregulation of acetylated histone H3 
protein (AcH3) after knocking down both HDAC1 and 2 together. This acetylation of 
histone H3 protein further demonstrated a reduction of global HDAC activity in the 
cell. 
Similar to HEP3B cells, while knocking down HDAC2 has no effect on the 
global HDAC activity of HCT116 cells, knocking down HDAC1 can partially reduce 
HDAC activity (Figure 4.18). In the HCT116 p53-/- cells which do not produce 
functional HDAC2 protein, their basal HDAC activity is similar to that of HCT116 
cells. However, when HDAC1 was knocked down in the HCT116 p53-/- cells, their 
HDAC activity level dropped dramatically. 
4.4.2 Construction and verification of HDAC1 and HDAC2 wildtype and 
mutant expression plasmids 
Both HDAC1 and 2 are enzymes that are known to deacetylate histone tails. 
To study the role of HDAC1 and HDAC2 in contributing to the HDAC activity in the 
cell, overexpression plasmids were constructed. Full length HDAC1 and HDAC2 
were cloned into pcDNA3.1 vector. Site-directed mutagenesis was done to mutate 2 
nucleotides within the catalytic domain of HDAC1 to generate an enzyme-dead 
mutant based on Hassig et al. (Hassig et al., 1998). To verify the constructed 
plasmids, we tried to overexpress them in HEP3B cells. While both the wildtype and 
mutant HDAC1 plasmid can be overexpressed, the HDAC2 plasmids failed to be 




Figure 4.18 In HCT116 p53-/- cells which did not have endogenous 
HDAC2, knockdown of HDAC1 can dramatically reduce HDAC 
activity. HCT116 and HCT116 p53-/- cells were transfected with 
siRNA against HDAC1 (H1) or HDAC2 (H2) or non-silencing control 
(Scr) for 48 hours before the nuclear extract was used to test for HDAC 
activity. Negative control (Neg Ctrl) was performed by omitting the 
addition of the nuclear extract to the substrate in the assay. Knocking 
down HDAC1, but not HDAC2, can partially reduce HDAC activity in 
HCT116 cells. In HCT116 p53-/- cells which do not produce functional 
HDAC2 proteins, knocking down HDAC1 alone can markedly reduce 





Figure 4.19 HDAC plasmid cannot be overexpressed at protein level. A, 
HEP3B cells were transfected with either pcDNA empty vector control (PC), 
HDAC1 wildtype plasmid (HD1), HDAC1 mutant plasmid (M1), HDAC2 
wildtype plasmid (HD2), or HDAC2 mutant plasmid (M2) for 48 hours 
before protein extraction. Western blots showed the protein expression of 
HDAC1 and HDAC2 proteins. GAPDH was used as loading control. While 
HDAC1 wildtype and mutant plasmid can overexpress  the protein, both the 
HDAC2 plasmids did not. B, Both the HDAC2 wildtype and mutant 
plasmids failed to be overexpressed in HCT116 cells. C, HCT116 cells were 
transfected with either HDAC2 overexpression vector (HDAC2) or pcDNA 
empty vector (pcDNA) for 48hours before RNA extraction, followed by real 
time RT-PCR using Roche Lightcycler. The HDAC2 mRNA was 
overexpressed over 500 folds. 
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we attempt to overexpress HDAC2 in HCT116 cells (Figure 4.19B), even though the 
plasmid was overexpressed at the mRNA level (Figure 4.19C). Therefore, we used the 
HCT116 p53-/- cell line which has a deletion on its HDAC2 DNA sequence due to 
microsatellite instability (Figure 4.20A). This led to a frameshift mutation and an 
early stop codon, resulting in a protein with only 30 amino acids instead of the full-
length 488 amino acids, and cannot be detected on Western blot (Figure 4.20B). 
Without endogenous expression of HDAC2, both HDAC2 wildtype and mutant 
protein can be expressed in this HCT116 p53-/- cell line, along with HDAC1 (Figure 
4.20C). While the HDAC1 plasmid of the same sequence has been previously verified 
by Hassig et al. (1998), the HDAC2 plasmid was not. After immunoprecipitating the 
wildtype and mutant HDAC2 plasmids using antibodies, we tested their HDAC 
activity after being overexpressed in the HCT116 p53-/- cells. Figure 4.21 confirmed 
that while the immunoprecipitated wildtype HDAC2 conferred HDAC activity, the 
mutant HDAC2 did not. 
4.4.3 Effect of wildtype and mutant HDAC1 plasmid on rescuing effect of 
HDAC1 and 2 knockdown  
To find out if the reduction of colony formation due to HDAC1 and 2 
knockdown can be rescued by the wildtype or enzyme-dead mutants of HDAC1 and 
2, a rescue experiment was performed. HEP3B cells were transfected with either the 
wildtype HDAC1+2 plasmid, mutant HDAC1+2 plasmid, or empty pcDNA vector 
before being transfected with siRNA against HDAC1+2 or non-silencing control. This 
was done in this order so that the overexpression plasmids had time to produce the 
HDAC proteins before the siRNA would prevent their expression. However, only 
HDAC1, but not HDAC2, protein expression was rescued partially (Figure 4.22A). 




Figure 4.20 Both HDAC1 and HDAC2 wildtype and mutant plasmids 
can be overexpressed in HCT116 p53-/- cells. A, HCT116 p53-/- cells 
contained a single nucleotide deletion which resulted in a frameshift 
mutation. Sequencing of the cDNA from HCT116 wildtype cells showed 9 
adenosine/thymidine residues while that from the same region of the 
HCT116 p53-/- cells showed only 8 adenosine/thymidine residues. B, 
Unlike HCT116 cells, the HCT116 p53-/- cells do not have endogenous 
full-length HDAC2 protein. C , HCT116 p53-/- cells were transfected with 
either pcDNA empty vector control (PC), HDAC1 wildtype plasmid 
(HD1), HDAC1 mutant plasmid (M1), HDAC2 wildtype plasmid (HD2), 
or HDAC2 mutant plasmid (M2) for 48 hours before protein extraction. 
Western blots showed the protein expression of HDAC1 and HDAC2 





Figure 4.21 HDAC activity after overexpression of HDAC2  
wildtype and mutant plasmids in HCT116 p53-/- cells which lack 
endogenous full-length HDAC2. Cells were transfected with either 
wildtype HDAC2 (HDAC2) or  mutant HDAC2 (Mutant H2) or 
empty vector control (pcDNA ctrl) for 48 hours before the nuclear 
extract was immunoprecipitated with anti-HDAC2 antibodies and 
tested for HDAC activity. The wildtype HDAC2 plasmid was verified 





Figure 4.22. Rescue experiment. HEP3B cells were transfected with 
either wildtype HDAC1 and 2 plasmids (Hd1+2), or mutant HDAC1 and 
2 plasmids (M1+2), or empty vector pcDNA  (PC ctrl). They were 
allowed to recover overnight before being transfected with either 
HDAC1 and 2 siRNA (H1+2) or non-silencing control (Scr). The cells 
were allowed to recover overnight before being replated for colony 
formation. A, Western blot shows the overexpression plasmids can 
rescue the expression of HDAC1 but not that of HDAC2. GAPDH was 
used as loading control. B, The overexpression of the wildtype plasmids, 
but not the mutant, can partially rescue the reduction of colony 




overexpressed except in a cell line that did not produce endogenous full-length 
HDAC2. Nevertheless, the partial rescue in HDAC1 expression was able to partially 
rescue the reduction of colony formation due to knockdown of both HDAC1 and 2 
(Figure 4.22B). This effect was only observed when the wildtype plasmids, but not 
the mutant, were used. HDAC activity assay showed that the HDAC activity in the 
cell was increased only when the wildtype but not the mutant plasmid was used in the 
rescue (Figure 4.23), attributing the partial rescue effect in colony formation to the 
enzymatic HDAC activity. 
4.4.4 Protective effects of wildtype HDAC1 against PXD101-induced cell death 
Using the HCT116 p53-/- cell line which lacks endogenous full length 
HDAC2, we were able to overexpress both the HDAC1 and 2 wildtype of mutant 
plasmids. Using this cell line, we examined the protective effect of HDAC1 and 2 
wildtype and mutant plasmids on cell death induced by HDAC inhibitor PXD101. 
Figure 4.24 showed the dose response of PXD101-induced cell death in the HCT116 
p53-/- cells. Increasing the dosage of PXD101 increased the percentage of cells 
undergoing apoptosis. Figure 4.25 showed that the overexpression of wildtype 
HDAC1 alone can partially protect the cells from PXD101-induced cell death. 
Overexpression of both HDAC1 and HDAC2 together did not increase the protective 
effect. The mutant HDAC1 failed to exhibit the same protective effect as the 
wildtype.  Figure 4.26 showed that overexpression of the wildtype HDAC1, either 
alone (p= 0.005) or together with wildtype HDAC2 (p=0.004), can increase global 
HDAC activity of the cells. However, the wildtype HDAC2 plasmid alone (p=0.067) 
did not significantly increase global HDAC activity. Also, neither the mutant HDAC1 
nor mutant HDAC2 can increase HDAC activity. In fact, mutant HDAC1 actually 




Figure 4.23 Rescue of HDAC activity. HEP3B cells were transfected 
with either wildtype HDAC1 and 2 plasmids (Hd1+2), or mutant HDAC1 
and 2 plasmids (M1+2), or empty vector pcDNA (PC ctrl). They were 
allowed to recover overnight before being transfected with HDAC1 and 2 
siRNAs. The nuclear extract was used to test for HDAC activity. The 
wildtype but not the mutant plasmids can rescue HDAC activity in these 
cells.  It must be noted that only the expression of HDAC1, but not 





Figure 4.24 Dose response of PXD101-induced apoptosis in HCT116 
p53-/- cells. Cells were treated with 100nM, 200nM, or 400nM PXD101 
or vehicle control for 48 hours. The subG1 fraction of cells, indicative of 
apoptotic cells, increased after treatment with increasing doses of the 
HDAC inhibitor PXD101.  
Figure 4.25 Protective effect of HDAC1 overexpression against PXD-
induced death in HCT116 p53-/- cells. Cells were transfected with the 
respective plasmids for 24 hours before they were treated with 300nM 
PXD101 or vehicle control for 48 hours. The subG1 fraction of cells, 
indicative of apoptotic cells, increased after treatment with PXD101. 
Overexpression of wildtype HDAC1, but not HDAC2, can partially 
rescue cells from PXD101 induced cell death. This protective effect was 




Figure 4.26 Effect of overexpressing wildtype and mutant HDAC1 
and 2 on global HDAC activity in HCT116 p53-/- cells. Cells were 
transfected with the respective plasmids for 48 hours before they were 
harvested for extraction of nuclear protein. A, Western blot showed 
the overexpression of the respective proteins. B, HDAC activity assay 
showed that the overexpression of HDAC1, but not HDAC2 alone, 
can increase global HDAC activity in the cells compare to the empty 
vector control (PC ctrl). Neither the mutant HDAC1 nor mutant 
HDAC2 can increase the global HDAC activity. Error bars showed 
standard deviations. The * indicates p<0.05 when compared to the 
empty vector PC control. 
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HDAC1. Together, these results demonstrated that restoring HDAC activity by 
overexpression of wildtype HDAC1 alone can partially protect the cells against drug-
induced cell death. 
 
4.5 Gene expression profiles of Hep3B cells after knockdown of HDAC1 or/and 
HDAC2 and PXD101 treatment 
4.5.1 Microarray analysis 
Microarray was used to analyze the gene expression profiles of HEP3B cells 
after knocking down HDAC1, HDAC2, or both. An HDAC inhibitor PXD101 was 
also used for comparison with the HDAC1 and 2 specific knockdown. Figure 4.27 
shows the number of genes upregulated and downregulated by each treatment and a 
heat map to illustrate the results. In the Illumina HumanRef-8 Beadchip which 
contained 24,526 coding transcripts in total, there were 2057 genes that were 
regulated at least 2 folds by the treatments. Of these, 409 genes were differentially 
regulated by silencing both HDAC1 and HDAC2 together but not individually. 
Classification of the differentially regulated genes were done based on Gene 
Ontogeny to show the molecular functions, biological processes and cellular 
components to which these genes belong (Figure 4.28). Using the Protein ANalysis 
THrough Evolutionary Relationships (PANTHER) pathway database, these genes 
were also grouped into the pathways with which they are associated (Thomas et al., 
2003). Table 4.4 shows the list of pathways. Of the 146 pathways that were hit, the 
ones which contained at least 5 genes that are regulated by knocking down both 
HDAC1 and 2 together were highlighted in bold. These are the angiogenesis pathway, 
the heterotrimeric G protein signalling pathway (G1 alpha and Gs alpha mediated), 




Figure 4.27 Microarray analysis to study effect of HDAC1 or/and 
HDAC2 knockdown on gene expression in HEP3B cell. A, Heat map to 
show gene expression in HEP3B cells after knocking down HDAC1 or/and 
2 with siRNAor treatment with PXD101. Red indicates upregulation and 
green indicates downregulation. 1, Non-silencing control SCR. 2, HDAC1 
siRNA. 3, HDAC2 siRNA. 4, HDAC1 and 2 siRNA. 5, Untransfected 
vehicle control. 6, PXD101 treatment.  A total of 2057 genes that were 
regulated by at least 2 folds compared to the controls after siRNA or 
PXD101 treatment were clustered. B, Table to show the number of genes 





Figure 4.28 Pie chart to show genes that were regulated at least 2 fold 
compared to the control after siRNA or PXD101 treatment in Hep3B cells. The 
classification of genes into molecular function (A), biological processes (B), and 







pathway, the platelet-derived growth factor (PDGF) signalling pathway, and the Wnt 
signalling pathway.  
4.5.2 Quantitative RT-PCR to validate selected genes 
To investigate the genes that mediate the effects of HDAC1 and 2 knockdown 
on reduced colony formation and increased apoptosis, some candidate were selected 
for validation by RT-PCR. These genes were selected if they were regulated 
significantly by HDAC inhibitor PXD101 treatment and by knocking down both 
HDAC1 and 2 but not individually. Genes that have known some functions in cell 
survival and proliferation were shortlisted.  Table 4.5 shows the list of 9 genes 
selected, with their fold changes after each treatment and their functions. The genes 
that were upregulated after silencing both HDAC1 and 2 were CYGB, DYRK4, 
GALR2, GLUT3, MAGEC2, NMES1, and NOTCH3; the downregulated genes were 
LOX and LOXL4. Figure 4.29 shows the quantitative RT-PCR results of these genes. 
Their relative mRNA expression was consistent with the microarray data. 
4.5.3 Western Blot to validate gene candidates 
After validating the RNA expression of the candidate genes, Western blot was 
done to check the protein expression of some of these candidate genes after silencing 
HDAC1 or/and 2. Figure 4.30 showed that among the upregulated genes after 
HDAC1+2 knockdown, only CYGB, GALR2 and PLCg2 demonstrated upregulation 
at the protein level, while MAGEC2 and NMES did not. On the other hand, both of 
the downregulated genes selected (LOX and LOXL4) showed downregulation at 
protein level consistent with the microarray data.  
4.5.4 Effect of HDAC-regulated genes LOX and LOXL4 on colony formation 










Figure 4.29 Validation of gene expression by quantitative real time RT-
PCR. HEP3B cells were transfected with siRNA against HDAC1 (H1), or 
HDAC2 (H2), or both (H1+2), or non-silencing control (Scr) for 72 hours, or 
treated with 2000nM PXD101 (PXD) for 24 hours. RNA was extracted and used 
in real time quantitative RT-PCR using primers for the respective genes. Each 
sample was done in duplicates and the average was used to calculate the mRNA 














Figure 4.30 Validation of gene expression by Western blot. HEP3B cells were 
transfected with siRNA against either HDAC1 (H1) or HDAC2 (H2) or both 
(H1+2) or non-silencing control (Scr) for 72 hours. Cells were harvested and 
total protein extracted and quantified. Western blot was done using antibody 
against the respective proteins shown above.  The * indicates the gene s 
downregulated while the rest were upregulated after HDAC1+2 knockdown 
based on microarray data.  GAPDH was used as loading control. 
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There were 2 downregulated genes selected to test if they could be possible 
mediators of HDAC1+2 knockdown-induced cell death: LOX and LOXL4. Both of 
them belong to the LOX family of enzymes. From the microarray, LOX was found to 
be downregulated 24.4 fold by HDAC1+2 knockdown, and 8.8 fold by PXD101 
treatment.  LOXL4 was found to be downregulated 7.1 fold by HDAC1+2 
knockdown, and 4.3 fold by PXD101 treatment. 
The expression of LOX and LOXL4 were silenced using siRNA in HEP3B 
cells. Figure 4.31 shows that the siRNA against LOX and LOXL4 can efficiently 
knockdown specific genes. However, the knockdown of LOX or LOXL4 did not 
change colony formation in the HEP3B cells (Figure 4.32).  In fact, the knockdown of 
both LOX and LOXL4 together increased the colony formation in these cells 
(p=0.025). 
4.5.5 Effect of HDAC-regulated gene GALR2 on colony formation in HEP3B 
cells 
The GALR2 gene was selected to test if its upregulation is a possible mediator 
of HDAC1+2 knockdown-induced cell death. From the microarray, GALR2 was 
found to be upregulated 5.7 fold by HDAC1+2 knockdown, and 3.5 fold by PXD101 
treatment. The pCMV-GALR2 overexpression plasmid was requested from Dr 
Kanazawa from Jichi Medical University in Japan. Figure 4.33A shows that the 
pCMV-GALR2 plasmid can overexpress the gene in the HEP3B cells. The GALR2 
overexpression slightly reduced colony formation in the HEP3B cells (Figure 4.33B), 







Figure 4.31 RT-PCR and Western blot to show efficiency of LOX and 
LOXL4 knockdown. A, HEP3B cells were transfected with either LOX 
siRNA (3 sequences) for 72 hours. Cells were harvested and RNA extracted. 
Real time quantitative RT-PCT was done to shown the LOX mRNA 
expression after each siRNA treatment (LOXA, B, or C), as well as when the 
3 sequences of siRNA were combined together (LOXABC). All 3 siRNA 
sequences were able to knockdown LOX expression effectively so they were 
pooled together  for use in subsequent experiments. B, The pooled LOX 
siRNA was able to knock down LOX protein expression as shown in the 
Western blot. GAPDH was used as loading control. C, HEP3B cells were 
transfected with a mixture of 2 siRNA sequences against  LOXL4 (L4A an 
L4B), or both (L4) or the non-silencing control (Scr) for 72 hours before 
being harvested for protein for Western blot. The individual siRNA 
sequences as well as the pooled siRNA were able to knock down LOXL4 




Figure  4.32  Effect of knocking down LOX or LOXL4 in HEP3B 
cells. Cells were transfected with LOX siRNA (LOX), or LOXL4 
siRNA (L4), or both (LOX+L4) or non-silencing control siRNA (SCR). 
They were allowed to recover overnight before being counted and 
replated at low density. After 10 days, the colonies were stained with 
crystal violet and the wells were imaged and the number of colonies 
counted. The average number of colonies in each of the triplicate wells 
were plotted against the treatment. The error bars showed standard 
deviations. The knockdown of LOX or  LOXL4 did not change the 
ability of the cells to form colonies. However, the knockdown of both 
LOX and LOXL4 actually increased the colony formation in these cells 




Figure  4.33  Effect of overexpressing GalR2 in HEP3B cells. Cells 
were transfected with pCMV-GalR2 plasmid (GalR2), or empty vector 
control (PC ctrl). They were allowed to recover overnight before being 
counted and replated.  A, Western blot to show the overexpression of 
the GalR2 compared to the empty vector control (PC ctrl). B, Eight 
days after replating, the colonies were stained with crystal violet and 
the wells were imaged and the number of colonies counted.The average 
number of colonies in each of the triplicate wells were plotted against 
the treatment. There was slight reduction in the number of colonies 
after overexpression of GalR2, but it was not statistically significant 










 CHAPTER 5 DISCUSSION 
 
5.1 Upregulation of HDAC1 and HDAC2 in hepatocellular carcinoma (HCC) 
We examined expression of both HDAC1 and 2 in 28 pairs of HCC and their 
matched adjacent non-tumor tissues by Western blot and 179 pairs of HCC by tissue 
microarray. To minimize the effect of variation among patients, the expression of 
HDAC1 and 2 in each tumor was normalized to the matched adjacent non-tumor in 
the same patient as control. Our results consistently showed that both HDAC1 and 
HDAC2 were upregulated in the majority of the HCC samples compared to the 
matched adjacent non-tumor controls. The level of protein upregulation can be 7-fold 
or higher in some samples, as quantitated by densitometry after Western blot. Based 
on immunohistochemistry, localization of HDAC1 and 2 were found to be strongest 
in the nucleus, which is consistent with the known functions of class I HDACs as 
regulators of gene expressions.  
Numerous studies have found HDAC1 and HDAC2 to be upregulated in other 
cancers. For example, HDAC1 and 2 were upregulated in renal cancer, prostate 
cancer, colorectal cancer, and gastric cancer (Fritzsche et al., 2008; Weichert et al., 
2008b; Weichert et al., 2008c; Weichert et al., 2008d). In liver cancers, Rikimaru et al 
also reported the high expression of HDAC1 in HCC samples but they did not look at 
HDAC2 expression (Rikimaru et al., 2007). Another group found class II HDACs 
(HDAC4, 5, 6, 7, and 10) to be higher in HCC than in normal and cirrhotic livers, but 
they did not study the expression of class I HDACs (Bai et al., 2008).  
Samples with downregulated HDAC1 and HDAC2 in our HCC tissues 
compared to the matched adjacent non-tumors were very few (3 out of 179 samples). 
However, there have been reports of the downregulation or loss of HDACs in cancer. 
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In endometrial adenocarcinoma, there was one report of fewer number of HDAC1-
positive staining of the stromal and epithelial cells in the tumor tissues compared to 
the normal tissues (Krusche et al., 2007). For HDAC2, a frameshift mutation has been 
reported in colorectal cancer (Ropero et al., 2006). This mutation led to the loss of 
HDAC2 protein and was found in sporadic carcinomas with microsatellite instability 
as well as in tumors in people with hereditary nonpolyposis colorectal cancer 
syndrome.  
While our results clearly showed upregulation of both HDAC1 and 2 in HCC 
tumor samples, they only reflected the protein expression level without demonstrating 
that the HDACs are enzymatically active. HDAC activity can be modulated by post-
translation modification such as phosphorylation and sumoylation (David et al., 2002; 
Galasinski et al., 2002; Tsai and Seto, 2002). Therefore, it will be interesting to 
determine the acetylation status of  histone H3 and H4 using specific antibodies in the 
clinical samples as a surrogate measure of HDAC activity in future studies. 
 
5.2 Correlation between HDAC1 and HDAC2 expression with 
clinicopathological parameters 
5.2.1 Patient survival 
HDAC1 and 2 indices for each patient were obtained based on the level of 
upregulation of HDAC1 and HDAC2 in the tumor compared to the matched non-
tumor samples. The patients were categorized into either high or low expression for 
HDAC1 and HDAC2 and the cumulative survival ratio of the population of samples 
was plotted over 6 years. Kaplan-Meier analysis showed that those with higher 
upregulation of HDAC1 have poorer survival than those with no or low upregulation. 
When multivariate analysis was done using cox regression, HDAC1 was the 
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independent factor for poor prognosis. On the other hand, there is no statistically 
significant difference for patients with high or no/low HDAC2 upregulation in terms 
of survival. 
Various groups have studied the correlation of HDAC1 and 2 expressions with 
patient survival in different types of cancer. Of these, neither HDAC1 nor HDAC2 
was found to have statistically significant effect on patient survival in cutaneous T 
cell lymphoma, ovarian serous carcinoma, and endometrial endometriod carcinoma 
(Marquard et al., 2008; Weichert et al., 2008a). On the other hand, HDAC1, but not 
HDAC2, was found to be a significant prognosis factor for patient survival in ovarian 
endometriod carcinoma (Weichert et al., 2008a); while HDAC2, but not HDAC1, was 
found to be significant in colorectal cancer and prostate cancer (Weichert et al., 2008c; 
Weichert et al., 2008d); and both HDAC1 and 2 were significant in gastric cancer 
(Weichert et al., 2008b). Table 5.1 summarized these findings. 
Table 5.1 Significance of HDAC1 and HDAC2 expressions on patient survival in 
the various cancers. P-values< 0.05 were considered significant and were printed in 
bold. 
Type of Cancer HDAC Significance Reference 
Cutaneous T-cell lymphoma 
(n=59) 
HDAC1 P=0.3 (Marquard et al., 2008) 
HDAC2 P=0.94 
Ovarian serous carcinoma 
(n=176) 












HDAC1 P=0.35 (Weichert et al., 2008d) 
HDAC2 P=0.03 
Prostate carcinoma (n=145) HDAC1 P=0.81 (Weichert et al., 2008c) 
HDAC2 P=0.02 
Gastric carcinoma (n=123) HDAC1 P<0.01 (Weichert et al., 2008b) 
HDAC2 P=0.02 
 
In HCC, Rikimaru et al. found that the survival rate in patients with high 
HDAC1 expression is lower (Rikimaru et al., 2007). This is consistent with our 
112 
 
findings. In addition, they also demonstrated that high HDAC1 expression also 
indicated higher occurrence of cancer cell invasion into the portal vein, poorer 
histological differentiation, and a more advanced TNM stage. These suggested a role 
for HDAC1 in tumor aggressiveness and cell differentiation. However, they did not 
report if they had examined the expression of HDAC2 in their study.  
Using clinical patient samples with matched controls, our study had 
demonstrated that HDAC1 but not HDAC2 is a significant prognostic factor for 
survival in HCC. 
5.2.2 Other parameters 
Neither HDAC1 nor HDAC2 expression was found to be correlated with most 
of the other clinicopathological parameters examined, such as race, smoking history, 
group staging or fibrosis. However, higher HDAC1 expression was found to be 
associated with hepatitis B virus (HBV) status of the patient. A study by Yoo et al. 
showed that HBV x-protein (HBx) can induce expression of HDAC1 at the 
transcription level (Yoo et al., 2008). Also, the protein expression of HDAC1 was 
increased in the hepatocytes of HBx transgenic mice. In addition, HBx was also 
known to interact with HDAC1 to cause transcription repression of other genes (Shon 
et al., 2009). The HBx protein can recruit HDAC1 to the promoter of insulin-like 
growth factor binding protein 3 (IGFBP3) and repress its gene expression via Sp1. 
Together these show that the correlation between HBV and HDAC1 in our clinical 
samples has physiological relevance, and HDAC1 expression is important in the 
development of HCC.    
There was also association between pre-operative treatment and 
downregulation of HDAC1 in the tumor samples. The pre-operative treatment in these 
cases was embolization to shrink the tumor before resection surgery. It is not clear 
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how this may reduce HDAC1 expression. It could be due to the reduction of blood 
supply to the tumor cells leading to reduction in certain factors that maybe required 
for HDAC1 expression. However, due to the small number of samples with 
downregulated HDAC1 (only 11 out of 179), it is not possible to draw any conclusion. 
 
5.3 Knockdown of HDAC1 and HDAC2 in the cells 
5.3.1 Compensatory effects observed in cells 
The siRNAs designed to knockdown HDAC1 and HDAC2 were specific and 
effective. Real time reverse transcription polymerase chain reaction (RT-PCR) results 
showed that the knockdown of HDAC1 did not affect HDAC2 and vice versa at the 
RNA level. However, at the protein level, the knockdown of HDAC1 slightly 
increased HDAC2 and vice versa, as shown by the Western blots.  
Other studies have also observed similar cross-regulation phenomenon. 
Montgomery et al. constructed conditional knockout mice with deletion of HDAC1 in 
the heart and did not observe any change in the RNA level of HDAC2 or any other 
HDACs (Montgomery et al., 2007). The RNA level of HDAC1 was also unchanged in 
their conditional knockout mice with deletion of HDAC2. However, they did not 
check the protein expressions. In another study, knocking out HDAC1 in mouse 
embryonic stem cells increased HDAC2 protein expression, although it was not able 
to compensate for the function of HDAC1 (Lagger et al., 2002). Furthermore, the 
restoration of HDAC1 in these mouse embryonic cells can bring the HDAC2 
expression back down (Zupkovitz et al., 2006).  
Taken together, it seems likely that HDAC1 and HDAC2 are directly or 
indirectly involved in the regulation of the protein expression of the other. Because of 
the conventional role of HDACs as transcriptional repressors, and HDAC1 has been 
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known to autoregulate its own expression transcriptionally (Schuettengruber et al., 
2003), it is tempting to postulate that the cross-regulation of HDAC1 and 2 also 
occurs at the transcription level. However, we did not observe any change in the 
HDAC2 mRNA after knocking down HDAC1 and vice versa based on our RT-PCR 
results. Therefore, HDAC1 and HDAC2 may be exerting its effect on each other by 
directly or indirectly affecting the translation or the post-translational modifications of 
the other, since HDACs have been known to deacetylate proteins other than histones. 
The detailed mechanisms would require further investigation. 
5.3.2 Compensatory effects not observed in clinical samples 
On the other hand, this cross-regulation may be context dependent. In our 
clinical samples, only 2 out of 11 liver tumors with downregulation of HDAC1 
showed a corresponding upregulation in HDAC2, and none of the 7 liver tumors with 
downregulation of HDAC2 showed a corresponding upregulation in HDAC1. 
Therefore, while this cross-regulation may be observed by manipulating the 
expression of HDAC1 and 2 under experimental conditions in cells, we have yet to 
observe it under physiological settings in our clinical samples.  
 
5.4 Effects of knocking down HDAC1 and HDAC2 
5.4.1 Reduction of colony formation and proliferation 
In all of the 3 liver cancer cell lines (HEP3B, HEPG2, and PLC5) and 1 colon 
cancer cell line (HCT116) tested, the knockdown of both HDAC1 and 2 together were 
able to reduce the clonogenic potential of the cells. Unlike other assays that quantify 
cell numbers or amount of cell death, colony formation assay measures the ability of 
individual cells to form colonies when plated at low density. When both HDAC1 and 
2 were knocked down, the cells failed to grow from single cells into colonies. 
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Growth of HEP3B cells was tracked over 6 days using the WST-1 assay which 
measures cell number based on their metabolic activity. The HDAC1+2 knockdown 
cells stopped proliferation between 72 to 96 hours post-transfection and the cell 
number began to decrease. From the Western blot data, the activation of caspase 3 and 
cleavage of its substrate PARP was observed from the 96 hours post-transfection. 
This time frame coincided with the WST-1 assay.  
While the knockdown of HDAC1 and 2 can reduce cell growth in cancer cells, 
it did not affect cells that are non-proliferating, such as postmitotic cardiac cells, 
resting fibroblasts, non-dividing hepatocytes and B cells (Haberland et al., 2009; 
Wilting et al., 2010; Yamaguchi et al., 2010). For example, Haberland et al. showed 
that while the deletion of both HDAC1 and 2 has little effects on confluent primary 
fibroblasts and calvarial osteoblasts, it resulted in mitotic catastrophe in proliferating 
primary cells (Haberland et al., 2009). Similarly, in a study by Khabele et al., ovarian 
cancer cell lines (A2780, SKOV-3 and OVCAR3) were found to be more sensitive to 
HDAC inhibitor FK228-induced cell death than primary normal ovarian cells with a 3 
to 5 folds difference in their half maximal inhibitory concentration (IC50) (Khabele et 
al., 2007). This differential effect of HDAC inhibition on cancer cells and non-
proliferating cell makes HDAC inhibitors effective chemotherapy drugs. 
5.4.2 Cell cycle profile showed increase in apoptosis 
Cell cycle profiling of the HEP3B cells showed that when HDAC1 and 2 were 
knocked down together, there was increase in the percentage of cells in the sub-G1 
phase, which is indicative of cells undergoing apoptosis characterized by fragmented 
DNA. There was consequently less cells in the G1 phase, but no change in the S phase 
or G2M phase.  
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Other studies also demonstrated increase in apoptosis after knocking down 
HDAC1 and 2. For example, conditional inactivation of HDAC1 and 2 in mouse 
embryonic fibroblasts (MEFs) resulted in increase in apoptosis (Yamaguchi et al., 
2010). However, unlike our case, there was also G1 phase arrest. Another study which 
used MEFs also found senescence-like G1 cell cycle arrest in the double HDAC1 and 
2 knockout cells, demonstrating the roles of these HDACs in controlling the G1 to S 
transition (Wilting et al., 2010). 
Most HDAC inhibitors are known to induce cell cycle arrest at the G1 to S 
phase boundary, mediated by the retinoblastoma protein (pRb) and related proteins 
(Haggarty et al., 2003). HDAC inhibitors can induce CDKN1A which encodes for p21 
protein that promotes hypophosphorylation of pRb, leading to cell cycle arrest 
(Richon et al., 2000). However, we did not observe this when we knockdown HDAC1 
and 2 together in the HEP3B cells. Our gene profiling by microarray showed a 2.3-
fold upregulation of CDKN1A mRNA after knocking down HDAC1 and 2 together, 
whereas the HDAC inhibitor PXD101 induced a 19.9 fold increase in the same cell 
line. Therefore, the slight induction of CDKN1A after knockdown of HDAC1 and 2 
may not be sufficient to induce cell cycle arrest. Instead, apoptosis was observed.  
Our data showed that there was activation of caspase 3 after knocking down 
HDAC1 and 2, as seen from the cleavage of the caspase 3 protein as well as the 
cleavage of its substrate PARP. While this clearly indicated the occurrence of 
apoptosis and the involvement of caspase 3, it cannot provide information on whether 
it was through the intrinsic or extrinsic pathway, or both. Our microarray data did not 
show any significant change in the expression of the various pro- or anti-apoptotic 
proteins in the mitochondrial (intrinsic) pathway or the molecules in the death-ligand 
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(extrinsic) pathway. Further studies can be done to study the apoptotic mechanisms 
involved. 
5.4.3 Significant effects observed only when both HDAC1 and HDAC2 are 
knocked down together 
For the colony formation assay, proliferation assay, and cell cycle profiling, 
the effects were observed only when both HDAC1 and 2 were knockdown together. 
Individual silencing of HDAC1 or HDAC2 did not show any significant effect. This 
could be due to HDAC1 and 2 having a compensatory effect on each other. In the 
absence of HDAC1, HDAC2 is able to compensate for the function of HDAC1, and 
vice versa. Therefore, knocking down just one of them did not have any significant 
effect on the cell. In fact, based on our Western blot data, knocking down one of them 
resulted in the increase of protein expression of the other. This further supports the 
hypothesis that such compensatory phenomenon occurs when only one of them was 
silenced. However, when both HDAC1 and 2 were knocked down together, the cell 
could no longer rely on the upregulation of either one of them to rescue the function 
of the other. 
Numerous studies have demonstrated that the loss of either HDAC1 or 
HDAC2 alone did not affect the normal development of various tissues and cell types, 
such as the heart, glial cells, neurons, and B cells (Montgomery et al., 2007; 
Montgomery et al., 2009; Yamaguchi et al., 2010; Ye et al., 2009). It takes the 
inactivation of both HDAC1 and 2 to disrupt the proliferation and differentiation of 
various normal and tumorigenic cells. 
On the other hand, there are also evidences for the unique functions of 
HDAC1 and 2 that cannot be compensated by the other. For example, the deletion of 
HDAC1, but not HDAC2, resulted in embryonic lethality in mouse due to 
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proliferation defects of the cells (Lagger et al., 2002). This demonstrated the critical 
role of HDAC1 in early embryogenesis, which cannot be substituted by HDAC2. In 
addition, when HDAC2 knockout mice were crossed with the tumor-prone APC (min) 
mice, there was reduction in the number of intestinal tumors (Zimmermann et al., 
2007). Taken together, these data showed that while there is redundancy of HDAC1 
and HDAC2 functions, there are also unique roles of HDAC1 and 2 under specific 
circumstances. 
 
5.5 Role of enzyme activity in function of HDAC1 and 2 
5.5.1 Synergistic reduction of HDAC activity after HDAC1 and 2 knockdown 
HDAC activity assay was used to measure the global HDAC activity in 
HEP3B cells after knocking down HDAC1 and 2 individually and together. Our 
results showed that while the knockdown of HDAC1 alone partially reduced global 
HDAC activity, the knockdown of HDAC2 alone had no effect. When both HDAC1 
and 2 were silenced together, there was synergistic reduction of global HDAC activity. 
Using the HCT116 p53-/- cells which do not produce endogenous HDAC2, we 
showed that the knockdown of HDAC1 alone resulted in a dramatic reduction of 
HDAC activity, similar to the fold change observed when both HDAC1 and 2 were 
knocked down together in cells that have endogenous HDAC1 and 2. 
From our Western blot data described earlier, we observed a compensatory 
effect of HDAC1 and 2 on each other in terms of protein expression. This can explain 
why knocking down HDAC2 alone did not affect change in global HDAC activity. It 
is due to the compensatory upregulation of HDAC1. The knockdown of both HDAC1 
and 2 eliminate such compensatory effect, and there was consequently a significant 
drop in the global HDAC activity. Nevertheless, we observed a partial reduction in 
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HDAC activity when HDAC1 was knockdown alone. This shows that the resultant 
upregulation of HDAC2 was not able to compensate for the reduction of HDAC 
activity after HDAC1 knockdown, possibly because HDAC1 is the major contributor 
to the cell’s overall HDAC activity.   
In addition, a series of in vitro studies demonstrated that HDAC1 and HDAC2 
activities can be regulated by their own acetylation status. The deacetylase activity of 
HDAC1 was inhibited when it was acetylated by the HAT p300 (Qiu et al., 2006).  
Although HDAC2 cannot be acetylated by p300, its activity was inhibited by the 
acetylated HDAC1 (Luo et al., 2009). Moreover, the acetylated HDAC1 can 
indirectly inhibit activity of HDAC2 by heterodimerization. Each HDAC1/2 
heterodimer requires 2 functional deacetylases to be active. Therefore, if one of them 
was inactive either by acetylation or inhibition of its catalytic domain, the heterodimer 
would be rendered non-functional as a deacetylase. 
5.5.2 Effect of knocking down HDAC1 and 2 on colony formation is dependent 
on enzymatic activity 
The HDAC1 and 2 wildtype and enzyme-dead mutant plasmids were 
constructed to test if the effect of knocking down HDAC1 and 2 on colony formation 
reduction can be rescued. Because HDAC2, both wildtype and mutant, cannot be 
overexpressed in cells that have endogenous HDAC2, only HDAC1 was 
overexpressed in the rescue experiment. Wildtype HDAC1, but not the enzyme-dead 
HDAC1 mutant, was able to partially but significantly rescue the reduction in colony 
formation after knockdown of both HDAC1 and 2. This rescue of the colony 
formation is attributed to the rescue of HDAC activity as evident from the HDAC 
activity assay, where the wildtype but not the enzyme-dead mutant HDAC1 plasmid 
can rescue HDAC activity in the presence of siRNA against HDAC1 and 2. In other 
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words, although we did not perform a full rescue of HDAC1 and 2, we were able to 
partially rescue the colony formation when we partially rescue the HDAC activity of 
the cell. 
5.5.3 Protective effect of HDAC1 against PXD101-induced apoptosis 
We used the HCT116 p53-/- cells to study the effect of overexpressing 
wildtype and mutant HDAC1 and 2, because we were unable to overexpress HDAC2 
protein in other cell lines. This cell line has a mutation in the HDAC2 gene due to 
microsatellite instability (Figure 4.20). Therefore, it does not produce the full length 
HDAC2 protein endogenously, making overexpression possible. 
The HDAC inhibitor PXD101 can induce apoptosis in HCT116 p53-/- cells in 
a dose-dependent manner. The overexpression of wildtype HDAC1 can rescue the 
cells from the PXD101-induced apoptosis. This protective effect is dependent on the 
HDAC activity as the enzyme-dead mutant of HDAC1 did not rescue the cells from 
apoptosis. Neither the HDAC2 wildtype nor mutant plasmid was able to exert such 
protective effect. This can be explained using the data from the HDAC activity assay, 
where only the overexpression of wildtype HDAC1, but not the mutant HDAC1, 
wildtype HDAC2, or mutant HDAC2, can increase the HDAC activity of the cells. 
Therefore, cancer cells with a higher expression of HDAC1 would be more resistant 
to HDAC inhibitors induced cell death.  
It is interesting to note that while the overexpression of HDAC1 can increase 
HDAC activity in the cell, the overexpression of HDAC2 did not. This is consistent 
with our previous finding in another cell line where the knockdown of HDAC1 
partially reduced HDAC activity but the knockdown of HDAC2 did not. This further 
supports HDAC1 as the major contributor to the cell’s global HDAC activity. 
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In addition, the overexpression of mutant HDAC1 actually reduced the HDAC 
activity of the cells. This could be due to the overexpressed enzyme dead mutant 
competing with the endogenous wildtype HDAC1 to bind to substrates, thus reducing 
overall HDAC activity. 
 
5.6  Apparent discrepancy between clinical samples and in vitro data 
While our clinical data demonstrated that HDAC1 upregulation alone was 
correlated with lower patient survival, our in vitro studies showed that knocking down 
HDAC1 alone did not reduce tumor cell survival measured by colony formation and 
apoptosis in the HCC cells. 
There could be several explanations for this apparent discrepancy. Firstly, 
HDAC1 may contribute to but not required in tumor cell survival and proliferation. 
During the process of carcinogenesis, a cell may gain survival and proliferation 
advantage by acquiring an upregulation in HDAC1. However, there may be other 
genetic and epigenetic events that occur concurrently, such that the removal of 
HDAC1 alone cannot kill the cell. Similar finding has been shown in a recent study of 
mitogen-activated protein kinase kinases (MEK), where MEK2 was found to be 
sufficient but not necessary for proliferation (Lee et al., 2011a). In that study, the 
knockdown of MEK2 alone has no effect on proliferation of the SK-MEL-28 
melanoma cells. Both MEK1 and MEK2 must be silenced together to reduce cell 
proliferation. On the other hand, the reconstitution of MEK2 activity alone in the 
presence of a pan-MEK inhibitor was sufficient to drive proliferation of these cells, 




Secondly, patient survival is influenced by many factors other than growth of 
the primary tumor alone. For example, metastatic potential of the tumor, the type of 
treatment and the resultant complications, many other factors that can affect the health 
of the patient can play important roles in determining how long the patient can live. 
Therefore, caution must be exercised when extrapolating in vitro data on tumor 
growth to the survival of the entire complex organism.  
 
5.7 Genes regulated by HDAC1 and HDAC2 
5.7.1 Comparing HDAC inhibitor PXD101 with knocking down HDAC1 and 2 
Using microarray, we profile the gene expression in HEP3B cells after 
knocking down HDAC1 and 2 individually and together, as well as treating the cells 
with the HDAC inhibitor PXD101. Consistent with other studies, there were genes 
that were upregulated as well as genes that were downregulated after treatment 
despite the major roles of HDACs as transcription repressors. In comparison, the 
number of genes regulated at least 2 fold by PXD101 treatment was comparable to 
that by silencing HDAC1 and 2 together. The magnitude of fold change was also 
comparable between PXD101 treatment and HDAC1+2 knockdown. For example, 
among the upregulated genes, the median fold change was 1.6 fold for PXD101 
treatment and 1.5 fold for HDAC1+2 knockdown. Therefore, the effectiveness of 
using the drug PXD101 as HDAC inhibitor to alter gene expressions seems to be 
similar to using HDAC1+2 knockdown.  
5.7.2 Genes differentially regulated when both HDAC1 and 2 were knocked 
down together but not individually 
In order to understand the mechanism by which HDAC1+2 knockdown affect 
cancer cell survival and proliferation, we focused on genes that were regulated after 
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knocking down both HDAC1 and 2 but not individually. From the microarray data, 
we identified 409 genes that were regulated at least 2 fold after knocking down both 
HDAC1 and 2, but not individually. These genes fall into a large collection of 
pathways with various functions. Some of these pathways have been implicated in 
cancer, such as the angiogenesis pathway and Wnt signaling pathway. Angiogenesis 
is the formation of new blood vessels, which is an important process needed for tumor 
growth and metastasis. The Wnt signaling pathway is important in organ development 
in many different species, but its aberrant activation is known to be associated with 
carcinogenesis (Barker et al., 2000).  
5.7.3 Identification of possible mediators of the effect of HDAC1+2 knockdown 
on colony formation 
We identified a list of genes that are similarly regulated by HDAC1+2 
knockdown and PXD101 treatment, but are not regulated by knocking down HDAC1 
or HDAC2 alone. Among these genes, we selected those with known functions in 
cancer cell survival and validated them using quantitative RT-PCR and Western blot. 
We further select 3 of these genes, lysyl oxidase (LOX), lysyl oxidase-like 4 
(LOXL4), and galanin receptor 2 (GALR2), to test their effect on colony formation.  
5.7.3.1 Lysyl oxidase (LOX) and lysyl oxidase-like 4 (LOXL4) 
LOX and LOXL4 were found to be downregulated by HDAC1+2 knockdown 
and PXD101 treatment. The LOX family includes 5 members: LOX, LOXL, LOXL2, 
LOX3, and LOXL4. They share a C-terminal copper-binding domain and catalytic 
domain, but differ in their N-terminal domains which determine their individual roles 
(Kim et al., 2008).  
LOX is a copper-containing amine oxidase that oxidize primary amine 
substrates to reactive aldehydes (Csiszar, 2001). It is important in the formation as 
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well as repair of the extracellular matrix by oxidizing lysine residues in elastin and 
collagen, stabilizing these fibrous proteins by initiating the formation of covalent 
crosslinkages (Kagan and Li, 2003). It has been shown to be involved in both tumor 
progression and tumor suppression, dependent on cellular location, cell type, and 
transformation status (Erler et al., 2006). For example, LOX was silenced by 
methylation in gastric cancer, and its re-introduction into the gastric cancer cell line 
MKN28 can reduce anchorage-independent cell growth (Kaneda et al., 2004). In 
addition, LOX was found to be downregulated in several oncogene-induced tumors 
and the knockdown of LOX can cause the transformation of rat fibroblasts 
(Giampuzzi et al., 2001). These evidences supported LOX as a putative tumor 
suppressor. On the other hand, breast cancer patients with high LOX expression in 
their tumors had poorer overall survival, and LOX was essential for hypoxia-induced 
metastasis (Erler et al., 2006). As such, the role of LOX in tumorigenesis and 
progression seems to remain unclear. 
LOXL4 has an N-terminus that contains 4 scavenger receptor cysteine rich 
(SRCR) domains, which are usually found in cell-membrane associated proteins 
functioning in cell adhesion (Hohenester et al., 1999). It is overexpressed in head and 
neck squamous cell carcinoma (Holtmeier et al., 2003), but has also been 
demonstrated to be silenced in human bladder cancer (Wu et al., 2007). In the HCC 
cell line PLC5, LOXL4 was demonstrated to be a target gene of TGFbeta1 and can 
inhibit TGFbeta1-induced cell motility (Kim et al., 2008).  
Because both LOX and LOXL4 was downregulated after HDAC 1+2 
knockdown as well as after PXD101 treatment, we used siRNA to silence their 
expression to test if it affects colony formation. When LOX and LOXL4 was knocked 
down individually in HEP3B cells, there was no effect on colony formation. When 
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they were knocked down together, there was actually an increase in the colony 
formation. This shows that it is unlikely for these 2 genes to be mediators of the 
HDAC1+2 knockdown-induced effect on colony formation. However, this data is 
consistent with the findings in some studies described earlier, which showed tumor 
suppressor characteristics in LOX and LOXL4. 
5.7.3.2 Galanin receptor 2 (GALR2) 
GALR2 was upregulated by HDAC1+2 knockdown and PXD101 treatment. 
Galanin is a neuropeptide with a wide range of distribution and effects, mediated 
through the 3 G proteins-coupled receptor subtypes: galanin receptors 1 to 3 (GALR1-
3). The expressions of galanin and its receptors are also found in some tumors such as 
glioblastoma, neuroblastoma, small cell lung cancer, and head and neck cancer 
(Berger et al., 2004; Berger et al., 2003; Wittau et al., 2000). Kanazawa and his team 
hypothesized GALR1 and GALR2 to be tumor suppressors and important therapeutic 
targets in head and neck squamous cell carcinoma (Kanazawa et al., 2010). They 
demonstrated that by overexpressing GALR1 in head and neck squamous cell 
carcinoma (HNSCC) cells that lack endogenous GALR1, galanin can suppress cell 
proliferation (Kanazawa et al., 2007), while GALR2 can induced caspase 3-dependent 
apoptosis (Kanazawa et al., 2009). 
In our HCC model system, the knockdown of HDAC1 and 2, as well as 
treatment with PXD101, increased expression of GALR2 but did not change that of 
GALR1 and GALR3 which are very lowly expressed in the HEP3B cells. The 
expression of the galanin ligand was not changed after HDAC1+2 knockdown, but 
was increased after PXD101 treatment. We tested if the overexpression of GALR2 
reduce colony formation in these cells using a pCMV-GALR2 plasmid we requested 
from Dr. Kanazawa’s lab. Our results showed that GALR2 can decrease colony 
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formation, but it was not statistically significant. There are various possibilities, one 
of which could be that the overexpression of the receptor GALR2 alone, without the 
galanin ligand, was not enough to trigger the downstream effect. Although the 
upregulation of galanin mRNA was not detected after HDAC1+2 knockdown base on 
our microarray data, there could still be an increase in the release of the galanin 
peptide. This can be verified by performing an ELIZA of the cell culture media after 
HDAC1+2 knockdown, or by immunofluorescence using anti-galanin antibody to 
detect the ligand binding to the cell surface. If there is increase galanin secretion and 
binding on the cell surface, then we need to perform the overexpression experiment 
with the addition of the galanin peptide to test the effect of colony formation. 
 
5.8 Future studies 
5.8.1 HDAC and the Wnt signaling pathway in HCC 
The differentially regulated genes after HDAC1+2 knockdown were mapped 
into many different pathways, one of which is the Wnt signaling pathway. The Wnt 
signaling pathway is important in normal liver physiology as well as pathology, by 
regulating differentiation, proliferation, and survival (Chiba et al., 2007; Thompson 
and Monga, 2007; Zeng et al., 2007). For example, activating mutation of Wnt 
signaling was found in 90% of colorectal cancers, though less frequently in HCC with 
a rate of about 18% (Giles et al., 2003). In addition, HDACs have been shown to 
epigenetically regulate genes in the Wnt signaling pathway. For example, the Wnt 
antagonist Dickkopf-1 (DKK1) was upregulated after treatment with HDAC inhibitor 
TSA in medulloblastoma cell line D283 (Vibhakar et al., 2007). Although we did not 
observe this upregulation from our data, we found the downregulation of the Wnt 
target genes, CCND1 (encodes for cyclin D1), as well as the upregulation of PRKCA 
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(encodes for protein kinase C alpha) which is involved in the Wnt/calcium pathway. 
Future work can be done to test the hypothesis that HDAC1+2 knockdown induced 
reduction of colony formation is mediated via the Wnt signaling pathway. In addition, 
we can test if there is any synergism in killing HCC cells using HDAC inhibitors with 
Wnt antagonist or inhibitors. 
5.8.2 Enzyme-independent functions of HDAC1 and HDAC2 
While we have established the enzyme-dependent functions of HDAC1 and 2 
in cancer cell survival, we have not addressed their enzyme-independent functions. 
From our microarray, there were genes that were regulated by HDAC1+2 knockdown 
but not the HDAC inhibitor PXD101. These are possible target genes of HDAC1 and 
2 that are regulated by mechanisms independent of the deacetylase activity. The 
functions of these genes and the pathway to which they belong can provide clues to 
their cellular effects. In addition, we can use the enzyme-dead mutants of HDAC1 and 
2 to test their functional effects on normal and cancer cells.  
5.8.3 Regulation of HDAC2 
It is interesting to note that although HDAC2 mRNA was increased 
dramatically after transfection of the HDAC2 plasmid, the protein cannot be 
overexpressed in cells which have endogenous HDAC2. Only in a cell line that has a 
mutation which resulted in a truncated protein did we manage to overexpress HDAC2. 
Previous studies have shown that HDAC2 can be degraded by proteosomal 
degradation, but we still failed to overexpress the HDAC2 protein even when 
proteosomal inhibitors such as MG132 and Lactacystin were used. It appears that 
there is translation or post-translational mechanisms that tightly regulate the 
expression of the HDAC2 but not the HDAC1 protein. Investigating this mechanism 










 CHAPTER 6 CONCLUSIONS 
 
Using clinical samples, we studied the expression of HDAC1 and 2 in 
hepatocellular carcinoma (HCC) and their correlation with clinicopathological 
parameters. We demonstrated that both HDAC1 and HDAC2 proteins were 
upregulated in HCC compared to the matched adjacent non-tumor tissue. The 
upregulation of HDAC1, but not HDAC2, was correlated with lower patient survival.  
While the knockdown of HDAC1 and 2 individually did not affect HCC cell survival, 
the knockdown of both proteins simultaneously led to reduction in cell proliferation 
and colony formation, as well as increase in apoptosis. This is attributed to the 
synergistic reduction of global HDAC activity in the cell. When we knocked down 
HDAC1 and 2 individually, we observed that they exert a compensatory effect on 
each other’s protein expression, thereby preventing the drop in HDAC activity needed 
to induce cell death and reduction in colony formation and proliferation. The partial 
restoration of HDAC activity in the cell can partially rescue the cells from the 
reduction in colony formation induced by knockdown of HDAC1 and 2. Furthermore, 
the overexpression of the wildtype but not the enzyme-dead mutant of HDAC1 can 
protect the cells from HDAC inhibitor induced apoptosis. Drug developers are 
seeking more isoform-specific HDAC inhibitors in hope of reducing off-target effects 
when treating cancer patients with HDAC inhibitors. However, it is important to note 
that the functional effect of inducing cell death may be compromised when only 
single isoform is inactivated due to the cross regulation of the various isoforms and 
compensatory effects. 
Using microarray, the gene expression profiles of the HCC cell line HEP3B 
was examined after knocking down HDAC1 or/and HDAC2, as well as after 
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treatment with the HDAC inhibitor PXD101. We found that the number of genes 
regulated and the magnitude of fold change was comparable between HDAC1+2 
knockdown and PXD101 treatment. We focused on the group of genes that were 
regulated by HDAC1+2 knockdown and PXD101 treatment, but not by knockdown of 
HDAC1 or HDAC2 alone. We validated a number of genes using RT-PCR and 
western blot, and selected 3 of them for testing their involvement in cell survival 
using our system. However, none of them showed statistically significant effects on 
colony formation in the HEP3B cells. 
When the HDAC1+2 knockdown regulated genes were grouped into the 
pathways to which they belong, we identified the Wnt signaling pathway as the one 
most significantly affected by the HDAC1+2 knockdown. This suggests that HDAC1 
and 2 may exert their effect on cell survival and proliferation through the Wnt 
signaling pathway. Further work needs to be done to test this hypothesis.  
In conclusion, we have demonstrated the significance of the upregulation of 
HDAC1 and 2 observed in hepatocellular carcinoma. Their contribution to the 
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1ml of DEPC was added per liter of dd water. Solution was shaken and left overnight 




To 800ml of dd water, add: 
 
 8g  Nacl 
 0.2g  KCl 
 0.24g  KH2PO4 
 1.44g  NaHPO4 
 
Adjust pH to 7.0 with HCl and add dd water to 1 liter. 
 
 
Reagents for DNA gel electrophoresis 
 
1% agarose gel 
 
Dissolve 0.5g DNase-free agarose in 50ml 0.5% TBE. Boil mixture in microwave 
oven. Allow to cool and add 1µl of 10mg/ml ethidium bromide solution. 
 
10X Tris-Borate EDA (TBE) buffer, pH 8.2 (per liter) 
 
 0.89M   Tris base 
 0.89M  Boric acid 
 0.01mM EDTA 
 
 
Reagents used for transformation 
 
LB agar medium (per liter) 
 




 10g  Bacto-trypton 
 5g  Bacto-yeast extract 
 10g  NaCl 
 20g  Agar 
 
Dissolve solutes. Adjust pH to 7.0 with 5N NaOH. Adjust volume to 1 liter with dd 
water. Sterilize by autoclaving. Cool to 50oC. Add antibiotics to desired concentration 
and pour onto petri dishes. Allow to solidify at room temperature and store at 4oC.  
 
LB broth (per liter) 
 
To 950ml of water, add: 
 
 10g  Bacto-trypton 
 5g  Bacto-yeast extract 
 10g  NaCl 
 
Dissolve solutes.  Adjust pH to 7.0 with 5N NaOH. Adjust volume to 1 liter with dd 
water. Sterilize by autoclaving. Store at 4oC.  
 
 
Reagents for Western Blot 
 
Lysis buffer for protein extraction 
 
 6M  Urea 
 1%   2-mercaptoethanol 
 50nM  Tris buffer pH 7.4 
 1%   SDS 
 
Dissolve all solution in 1X PBS. 
 
12% SDS-PAGE resolving gel (10ml) 
 
 4ml  30% Bis/Acrylamide 
 2.5ml  1.5 M Tris-HCl, pH 8.8 
 3.3ml  dd water 
 100µl  10% SDS 
 100µl  10% APS 
 4µl  Temed 
 
4% SDS-PAGE stacking gel (4ml) 
 
 0.53ml  30% Bis/Acrylamide 
 0.49ml  1.5 M Tris-HCl, pH 6.8 
 2.86ml  dd water 
 40µl  10% SDS 
 40µl  10% APS 




5X SDS/Glycine Buffer (per liter) 
 
 15.1g  Tris base 
 72g  Glycine 
 5g  SDS 
 
5X sample loading buffer 
  
 10%  SDS 
 50%  Glycerol 
 7%  DTT 
0.01%  bromophenol blue 
50mM  Tris pH 6.8 
  
Transfer buffer (per liter) 
 
 20%  ethanol 
 0.1%  SDS 
 14.4g  Glycine 
 3.03g  Tris 
 




 1%  NP40 
 1%  sodium deoxycholate 
 0.1%  SDS 
 0.15M  sodium chloride 
 50mM  Tris (pH 8.0) 
 
Cell lysis buffer to lyse cell membrane 
 
 0.65M  sucrose 
 20mM  Tris (pH 8.0) 
 10mM  magnesium chloride 
 2%  Triton-X 
 
NT buffer for nuclear extract 
 
 50mM  Tris (pH 7.4) 
 100mM sodium chloride 
 5mM  magnesium chloride 
 5mM  calcium chloride 
 1%  NP40 
 1%  Triton-X 
 10U  DNase I 
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